US20130338178A1 - Sirtuin modulators as inhibitors of cytomegalovirus - Google Patents

Sirtuin modulators as inhibitors of cytomegalovirus Download PDF

Info

Publication number
US20130338178A1
US20130338178A1 US13/982,779 US201213982779A US2013338178A1 US 20130338178 A1 US20130338178 A1 US 20130338178A1 US 201213982779 A US201213982779 A US 201213982779A US 2013338178 A1 US2013338178 A1 US 2013338178A1
Authority
US
United States
Prior art keywords
sirt1
virus
sirt2
sirtuin
sirtuins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/982,779
Inventor
Thomas Shenk
Emre Koyuncu
Ileana Cristea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Priority to US13/982,779 priority Critical patent/US20130338178A1/en
Publication of US20130338178A1 publication Critical patent/US20130338178A1/en
Assigned to THE TRUSTEES OF PRINCETON UNIVERSITY reassignment THE TRUSTEES OF PRINCETON UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRISTEA, Ileana, KOYUNCU, EMRE, SHENK, THOMAS
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: PRINCETON UNIVERSITY
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: PRINCETON UNIVERSITY
Assigned to NATIONAL INSTITUTES OF HEALTH reassignment NATIONAL INSTITUTES OF HEALTH CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: PRINCETON UNIVERSITY
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • SIRT1-7 Humans express seven sirtuins, termed SIRT1-7, all of which contain a conserved central NAD+-binding and catalytic domain.
  • Sirtuins are NAD+-dependent deacetylases and ADP-ribosyltransferases. Sirtuins deacetylate acyl-lysine residues of histones and other proteins. Given their requirement for NAD+, sirtuins are regulated by the pathways that produce the cofactor, and, as a result, are responsive to the metabolic state of cells. While their expression profiles can vary, sirtuins are ubiquitously expressed in a wide range of tissues.
  • Sirtuins are found in different cellular compartments: SIRT1, 6 and 7 are predominantly nuclear; SIRT3-5 are mitochondrial; and SIRT2 is a predominantly cytoplasmic resident. Drugs that activate sirtuins, such as resveratrol, appear to be well tolerated.
  • Resveratrol has been reported to inhibit varicella zoster virus replication in cultured cells (Docherty et al., 2006, Antiviral Res 72, 171-7); Resveratrol or overexpression of SIRT1 have been reported to inhibit the transactivation of the HIV-1 LTR in a transfection assay performed in cultured cells (Zhang et al., 2009, Life Sciences 85, 484-9); Resveratrol, SRT1720 or overexpression of SIRT1 have been reported to inhibit transgene expression from a replication-defective adenovirus in cultured neuronal cells (Picchione and Bhattacharjee, 2011, J Neurovirol, 17, 184-8); and HIV-1 Tat protein has been shown to negatively regulate SIRT1 (Kwon et al., 2008, Cell Host Microbe 3, 158-67).
  • the invention relates to a composition comprising a one or more sirtuin agonists.
  • Sirtuin agonists can be polyhydroxy stilbene compounds, polyhydroxy flavonoids (e.g., flavones, flavonols, isoflavones, or the like), polyhydroxy chalcone compounds, or combinations thereof.
  • Specific examples of contemplated agonists include:
  • x and y are each 0, 1, 2, 3, 4, or 5, and x+y ⁇ 1;
  • w and z are each 0, 1, 2, 3, 4, or 5, and w+z ⁇ 1;
  • R 1 is H or OH and R 2 is
  • sirtuin 5 agonists such as 3,5-dihydroxy-4′-chloro-trans-stilbene, dipyridamole, 3,5-dihydroxy-4′ethyl-trans-stilbene, 3,5-dihydroxy-4′-isopropyl-trans-stilbene, 3,5-dihydroxy-4′-methyl-trans-stilbene, resveratrol, 3,5-dihydroxy-4′thiomethyl-trans-stilbene, 3,5-dihydroxy-4′-carbomethoxy-trans-stilbene, isoliquiritgenin, 3,5-dihydro-4′nitro-trans-stilbene, 3,5-dihydroxy-4′azido-trans-stilbene, piceatannol, 3-methoxy-5-hydroxy-4′acetamido-trans-stilbene, 3,5-dihydroxy-4′acetoxy-trans-stilbene,
  • the invention relates to a composition comprising one or more sirtuin antagonists, or two or more sirtuin antagonists.
  • SIRT1/SIRT2 dual inhibitors include cambinol, tenovin 1, tenovin 6, salermide, sirtinol, and combinations thereof.
  • compositions comprising a SIRT1 inhibitor and a SIRT2 inhibitor.
  • compositions comprising a SIRT1 inhibitor and one or more of the group comprising a SIRT2 inhibitor, a SIRT3 inhibitor, a SIRT4 inhibitor, a SIRT5 inhibitor, a SIRT6 inhibitor, and a SIRT7 inhibitor.
  • SIRT inhibitors are readily identified through a screening assay.
  • a method of inhibiting both SIRT1 and SIRT2 comprising contacting both SIRT1 and SIRT2 with one or more antagonist compounds.
  • the antagonist e.g., a SIRT1/SIRT2 dual inhibitor or a SIRT1 inhibitor and a SIRT2 inhibitor
  • the antagonist is cambinol, tenovin 1, tenovin 6, salermide, sirtinol, or combinations thereof, or is one or more compounds as detailed below.
  • a method of inhibiting virus production comprising contacting a virus-infected cell with a SIRT1/SIRT2 dual inhibitor or a combination of a SIRT1 inhibitor and a SIRT2 inhibitor.
  • methods of inhibiting virus production comprising contacting a virus-infected cell with one or more inhibitors of two or more sirtuins, e.g., inhibiting SIRT1 and SIRT2; SIRT1 and SIRT3; SIRT1 and SIRT4; SIRT1 and SIRT5; SIRT1 and SIRT6; SIRT1 and SIRT7; SIRT2 and SIRT3; SIRT2 and SIRT4; SIRT2 and SIRT5; SIRT2 and SIRT6; SIRT2 and SIRT7; SIRT3 and SIRT4; SIRT3 and SIRT5; SIRT3 and SIRT6; SIRT3 and SIRT6; SIRT3 and SIRT6; SIRT3 and SIRT7; SIRT4 and SIRT5; SIRT4 and SIRT6; SIRT4 and SIRT7; SIRT5 and SIRT6; SIRT5 and SIRT7; and SIRT6 and SIRT7.
  • Also disclosed are methods of inhibiting three or more sirtuins e.g., non-limiting examples include inhibiting SIRT1, SIRT2, and SIRT3; inhibiting SIRT1, SIRT2, and SIRT5; and inhibiting SIRT1, SIRT3, and SIRT5).
  • the inhibitors can be the same, or can be different (e.g., an inhibitor to both SIRT2 and SIRT3 or a SIRT2 inhibitor and a SIRT3 inhibitor).
  • Also contemplated are methods of inhibiting virus production comprising containing a virus-infected cell with one or more inhibitors of three or more sirtuins.
  • the invention relates to a composition comprising one or more sirtuin antagonists that decreases the activity of both or each of SIRT1 and SIRT2.
  • the composition comprises a first compound that is a SIRT1 antagonist and a second compound that is a SIRT2 antagonist.
  • compositions comprising inhibitors of two or more sirtuins, e.g., inhibiting SIRT1 and SIRT2; SIRT1 and SIRT3; SIRT1 and SIRT4; SIRT1 and SIRT5; SIRT1 and SIRT6; SIRT1 and SIRT7; SIRT2 and SIRT3; SIRT2 and SIRT4; SIRT2 and SIRT5; SIRT2 and SIRT6; SIRT2 and SIRT7; SIRT3 and SIRT4; SIRT3 and SIRT5; SIRT3 and SIRT6; SIRT3 and SIRT7; SIRT4 and SIRT5; SIRT4 and SIRT6; SIRT4 and SIRT7; SIRT5 and SIRT6; SIRT5 and SIRT7; and SIRT6 and SIRT7.
  • SIRT1 and SIRT2 e.g., inhibiting SIRT1 and SIRT2; SIRT1 and SIRT3; SIRT1 and SIRT4; SIRT1 and SIRT5; SIRT1 and SIRT6; SIRT1
  • compositions comprising inhibitors of three or more sirtuins (e.g., non-limiting examples include SIRT1, SIRT2, and SIRT3 inhibitors; SIRT1, SIRT2, and SIRT5 inhibitors; and SIRT1, SIRT3, and SIRT5 inhibitors).
  • the inhibitors can be the same, or can be different (e.g., an inhibitor to both SIRT2 and SIRT3 or a SIRT2 inhibitor and a SIRT3 inhibitor).
  • the invention relates to a pharmaceutical composition including any of the compositions herein and a pharmaceutically acceptable carrier.
  • the invention relates to a method of treating disease comprising administering any of the compositions or pharmaceutical compositions herein to a patient, e.g., a patient suffering from a viral infection or a disorder associated with a viral infection.
  • FIG. 1 illustrates that inhibition of sirtuins enhances the production of infectious human cytomegalovirus (HCMV) progeny.
  • HCMV cytomegalovirus
  • FIG. 2 illustrates that the siRNAs used effectively reduced the levels of target sirtuin RNAs.
  • FIG. 3 illustrates that sirtuin agonists inhibit the production of infectious HCMV progeny.
  • FIG. 4 illustrates that a SIRT1 antagonist elevates the production of infectious virus, whereas an antagonist of both SIRT1 and SIRT2 inhibits the production of infectious HCMV progeny.
  • FIG. 5 illustrates that SIRT1/SIRT2 dual inhibitors tenovin-6 (left panel) and salermide (right panel) inhibit production of HCMV.
  • FIG. 6 illustrates that inhibition of HCMV replication by a dual SIRT1/SIRT2 inhibitor (Salermide) requires p53.
  • Right panel MRC5 cells stably expressing either p53 shRNA (shp53 MRC5) or non-targeting shRNA (NT MRC5) were infected with AD169 HCMV strain at a multiplicity of 0.5 IU/cell. At 2hpi, cells were treated either with 50 ⁇ M Salermide in DMSO or DMSO alone. This treatment was repeated at 48hpi. At 96hpi, virus-containing supernatants were collected and HCMV titers determined using infectious center assay in MRC5 cells. The result is representative of biological duplicates.
  • Left panel The knockdown of p53 in shp53 cell line was verified by Western Blot.
  • FIG. 7 illustrates that inhibition of sirtuins enhances the production of infectious herpes simplex virus type 1 (HSV1), adenovirus type 5 (Ad5) and influenza A (Flu A) progeny.
  • HSV1 herpes simplex virus type 1
  • Ad5 adenovirus type 5
  • FeA influenza A
  • top panel HSV1 KOS strain at a multiplicity of 1 infectious unit per cell, and after an additional 22 h supernatants were collected and virus yields were determined by infectious center assay in MRC5 cells
  • middle panel Ad5 at a multiplicity of 5 infectious units per cell, and after an additional 72 h, supernatants were collected and virus yields were determined by infectious center assay in HeLa cells
  • bottom panel influenza WSN/33/A strain at a multipicity of 0.5 infectious unit per cell and after an additional 22 h supernatants were collected and virus yields were determined by TCID50 assay in MDCK cells.
  • FIG. 8 illustrates dual Sirt1/Sirt2 inhibitors, Cambinol and Salermide, block the production of infectious Influenza A progeny.
  • MRC5 fibroblasts and MDCK cells were infected with the influenza WSN/33/A strain at a multiplicity of 0.01 TCID 50 /cell or PR8 strain at 0.1 TCID 50 /cell.
  • the medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 1 hpi, and the yield of influenza A was determined at 24 hpi by standard TCID 50 method on MDCK cells.
  • DMSO solvent
  • the marketed neuraminidase inhibitor, oseltamivir (TamiFlu®) was used as a comparator for the efficacy of tested compounds in the assay.
  • FIG. 9 illustrates that the dual Sirt1/Sirt2 inhibitor, Cambinol, cooperates with oseltamivir to block the production of infectious Influenza A progeny.
  • MDCK cells were infected with the influenza WSN/33/A strain at a multiplicity of 0.001 TCID 50 /cell. The medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 1 hpi, and the yield of influenza A was determined at 24 hpi by standard TCID 50 method on MDCK cells.
  • DMSO solvent
  • FIG. 10 illustrates that a SIRT1 antagonist enhances the production of infectious adenovirus (Ad5) progeny, but dual SIRT1/SIRT2 antagonists block the production of progeny.
  • MRC5 fibroblasts were infected with Ad5 at a multiplicity of 5 IU/cell. The medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 2 hpi, and the yield of Ad5 was determined at 72 hpi.
  • DMSO solvent
  • MRC5 fibroblasts were transfected with three different siRNAs targeting each of the seven sirtuins. 24 hours later, cells were infected with the HCMV AD169 strain at a multiplicity of 0.5 IU/cell, and the yield of HCMV was determined at 96 hpi. Sample 1 (left bar above each siRNA label) and sample 2 (right bar above each siRNA label) represent two independent knockdown experiments. As illustrated, siRNA-mediated inhibition of each of the seven sirtuins augments the production of HCMV progeny in cultured fibroblasts.
  • MRC5 cells were transfected with the indicated siRNAs; 24 hours later, cells were infected with the HCMV AD169 strain at a multiplicity of 0.5 IU/cell, and at 72 hpi the levels of sirtuin RNAs was determined by quantitative RT-qPCR by using GAPDH as the comparator. The level of knockdown induced by the siRNA that caused the greatest increase in virus yield for each sirtuin was monitored by quantitative RT-PCR, and each of the siRNAs proved to reduce the level of the targeted RNA.
  • MRC5 fibroblasts were infected with an HCMV variant expressing GFP tagged pUL99 (the product of late viral UL99 gene) at a multiplicity of 0.25 IU/cell.
  • Four hours after infection cells were treated with the indicated concentrations of resveratrol, CAY10602 or the carrier in which the drugs were dissolved (ethanol or DMSO).
  • Virus yield at 96 h after infection was determined by infecting fibroblasts and assaying IE1 expression by immunofluorescence 24 h later. Treatment with 100 ⁇ M resveratrol or 25 ⁇ M CAY10602 reduced the virus yield to below the limit of detection ( ⁇ 10 2 IU/ml).
  • MRC5 fibroblasts were infected with an HCMV variant expressing GFP tagged pUL99 (the product of late viral UL99 gene) at a multiplicity of 0.25 IU/cell.
  • Two hours after infection cells were treated with the indicated concentrations of SIRT1 inhibitor, EX-527; the dual SIRT1 and 2 inhibitor, Cambinol, or the carrier in which the drugs were dissolved (DMSO).
  • Virus yield at 96 h after infection was determined by infecting fibroblasts and assaying IE1 expression by immunofluorescence 24 h later. Treatment with 50 ⁇ M cambinol reduced the virus yield to below the limit of detection ( ⁇ 10 2 IU/ml).
  • Activation of one or more sirtuins is an embodiment.
  • Activation of one or more mitochondrial sirtuins is an embodiment.
  • a compound that increases sirtuin activity is referred to as a sirtuin agonist herein.
  • the compound can be a small molecule, nucleic acid, protein, or peptide.
  • sirtuin agonists contemplated include stilbene, flavone, isoflavone, flavanone, catechin, free radical protective compound, isonicotinamide, dipyridamole, ZM 336372 (3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamide), camptothecin, coumestrol, nordihydroguaiaretic acid, esculetin, SRT-1720 (Sirtris), SRT-1460 (Sirtris), SRT-2183 (Sirtris), analogs thereof, or combinations thereof.
  • the sirtuin agonist is a stilbene.
  • the stilbene is trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, or combinations thereof.
  • the agonist is a chalcone.
  • the chalcone is chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; or combinations thereof.
  • the agonist is a flavone.
  • the flavone is flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyflavone; 7,4′-dihydroxyflavone; 7,8,3′,4′-tetrahydroxyflavone; 3,6,2′,3′-tetrahydroxyflavone; 4′-hydroxyflavone; 5-hydroxyflavone; 5,4′-dihydroxyflavone; 5,7-d
  • the agonist is an isoflavone.
  • the isoflavone is daidzein, genistein, or combinations thereof.
  • the agonist is a flavanone.
  • the flavanone is naringenin; flavanone; 3,5,7,3′,4′-pentahydroxyflavanone; or combinations thereof.
  • the agonist is an anthocyanidin.
  • the anthocyanidin is pelargonidin chloride, cyanidin chloride, delphinidin chloride, or combinations thereof.
  • the agonist is a catechin.
  • the catechin is ( ⁇ )-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); ( ⁇ )-catechin (Hydroxy Sites: 3,5,7,3′,4′); ( ⁇ )-gallocatechin (Hydroxy Sites: 3,5,7,3′,4′,5′) (+)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (+)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); or combinations thereof.
  • the agonist is a free radical protective compound.
  • the free radical protective compound is Hinokitiol (b-Thujaplicin; 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one); L-(+)-Ergothioneine ((S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole4-ethanam-inium inner salt); Caffeic Acid Phenyl Ester; MC1-186 (3-Methyl-1-phenyl-2-pyrazolin-5-one); HBED (N,N′-Di-(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid H2O); Ambroxol (trans-4-(2-Amino-3,5-dibromobenzylamino)cyclohexane-HC; and U-83836E (( ⁇ )-2-(((S)-a-Car
  • the agonist is isonicotinamide or an analog of isonicotinamide.
  • the analog of isonicotinamide is .beta.-1′-5-methyl-nicotinamide-2′-deoxyribose; .beta.-D-1′-5-methyl-nico-tinamide-2′-deoxyribofuranoside; .beta.-1′-4,5-dimethyl-nicotinamide-2′-de-oxyribose; or .beta.-D-1′-4,5-dimethyl-nicotinamide-2′-deoxyribofuranoside.
  • isonicotinamide see U.S. Pat. Nos.
  • sirtuin agonists include trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyflavone; 7,4′-d
  • SIRT1 activating compounds have been described in the literature (for a review see Camins et al., 2010, Biochimica et Biophysica Acta 1799, 740-9, which is incorporated herein by reference as if fully set forth, (Table 1, below).
  • dihydropyridine and imidazol-[1,2-b]thiazole derivatives have been recently identified as novel SIRT1 agonists (Mia et al., 2009, J. Med Chem., 52, 5496-504, which is incorporated herein by reference as if fully set forth).
  • SRT1720 has a structure of
  • SRT1460 has a structure of
  • Resveratrol which is a polyphenol naturally found in some plants, is perhaps the best studied SIRT1 agonist. It increases SIRT1 activity by 1.5 fold at 46 ⁇ M and by 13 fold at 100 ⁇ M concentration (Howitz et al., 2003, Nature 425, 191-6). Resveratrol is selective for SIRT1 since it does not activate SIRT2 at 100 ⁇ M.
  • Resveratrol has been reported to inhibit HCMV replication previously (Evers et al., 2004, Antiviral Res 63, 85-95. In particular, it was concluded that Resveratrol only inhibited viral attachment and entry. In contrast, the work herein is the first to show that modulation of each of the seven sirtuins, including SIRT1 (a principal target of resveratrol), can influence viral replication and therefore predict that induction any one of the different known sirtuin activities will inhibit the production of HCMV progeny.
  • SIRT1 a principal target of resveratrol
  • SIRT1 activation on HCMV was further confirmed by employing a second SIRT1-activating compound, CAY10602, which has a structure:
  • CAY10602 was identified in a high-throughput screen as a compound that increases SIRT1-mediated deacetylation of a SIRT1-specific substrate and is a highly potent activator of SIRT1. It suppresses tumor necrosis factor alpha (TNF ⁇ ) release, a process which is linked to the activity of SIRT1, to a 10-fold greater extent than resveratrol. In line with this, CAY10602 showed a strong anti-HCMV effect. At 25 ⁇ M, CAY10602 almost completely inhibited pUL99 expression and reduced the yield of infectious HCMV below the detection limit ( FIG. 3 ). These results demonstrate that compounds activating SIRT1 block the production of infectious HCMV, and, therefore, have utility as antiviral drugs in the treatment of HCMV infections.
  • TNF ⁇ tumor necrosis factor alpha
  • sirtuin antagonist or “sirtuin inhibitor” refers to a compound that decreases sirtuin activity.
  • the compound can be a small molecule, nucleic acid, protein, or peptide.
  • the sirtuin antagonist is a dual antagonist, referring to its ability to decrease activity of two sirtuins.
  • SIRT1/SIRT2 dual inhibitors including, but not limited to cambinol, tenovin 6, tenovin 1, salermide, sirtinol, and combinations thereof. Further disclosed herein are combinations of a SIRT1 inhibitor and a SIRT2 inhibitor.
  • SIRT1 inhibitor is (S)-35 which has a structure
  • Cambinol inhibits NAD dependent deacetylase activity of both SIRT1 and SIRT2 (Heltweg et al., 2006, Cancer Res 66, 4368-77). Supporting the phenotype of the siRNA-mediated SIRT1 knockdown, 10 ⁇ M EX-527 increased the accumulation of late viral pUL99 protein (data not shown) and production of infectious HCMV progeny by a factor of ⁇ 4 fold in MRC5 fibroblasts ( FIG. 4 ).
  • the dual SIRT1/SIRT2 inhibitor Cambinol having a structure of
  • p53 plays a major role in cell-cycle control, it contributes to virus-induced apoptosis, and it is a direct activator of type I interferons that induce antiviral defense.
  • Several viruses require inactivation of p53 for efficient replication. Therefore these results demonstrate that multiple SIRT1/SIRT2 inhibitors have antiviral activity, and strongly predict that dual SIRT1 and SIRT2 inhibitors constitute a class of novel antiviral agents that inhibit HCMV as well as other viruses that require inactivation of p53.
  • Table 2 A list of non-limiting exemplary inhibitors is presented in Table 2.
  • Tenovin 1 has a structure of
  • Tenovin 6 has a structure of
  • Salermide has a structure of
  • Sirtinol has a structure of
  • Dual SIRT1/SIRT2 inhibitors are thought to act in part by blocking the ability of sirtuins to inhibit and consequently activating the tumor suppressor protein p53 (see Heltweg et al., 2006 and references therein). Therefore the possibility that p53 activity is needed for dual SIRT1/SIRT2 inhibitors to inhibit the production of HCMV progeny was tested ( FIG. 6 ). Results showed that salermide inhibited the production of HCMV progeny by a factor of nearly 80 in cells expressing p53. In contrast, the drug inhibited HCMV production by a factor of only about 5 in cells in which p53 levels were substantially reduced by knockdown with a p53-specific shRNA.
  • Dual SIRT1/SIRT2 inhibitors inhibit HCMV production at least in part through a p53-dependent mechanism.
  • Many viruses are known to block the activity of p53 as part of their strategy for successful replication. The block can be achieved by degradation of a substantial portion of the cellular p53, by interaction with a viral protein that inhibits p53 activity or by posttranslational modification of p53, including changes in acetylation status.
  • Dual SIRT1/SIRT2 inhibitors can relieve the block either by hyper-activation of residual active p53 or re-activation of inactivated p53. Therefore, the demonstration of a role for p53 predicts that any virus that inactivates p53 will be sensitive to dual SIRT1/SIRT2 inhibitors.
  • Contemplated viruses that inactivate p53 include, but are not limited to, Adenoviridae (Adenovirus, with E1B-55K as a p53 inactivating protein); Hepadnaviridae (HBV, with X protein a p53 inactivating protein); Herpesviridae (EBV, with LMP1 a p53 inactivating protein; HSV-1 with ICP0 as a p53 inactivating protein; HCMV, with IE1 as a p53 inactivating protein; KSHV with LANA as a p53 inactivating protein); Flaviviridae (HCV with NS5A as a p53 inactivating protein); Orthomixoviridae (Influenza A with NS1 as a p53 inactivating protein); Papillomaviridae (HPV with E6 as a p53 inactivating protein); Polyomaviridae (SV40 with Large T-antigen as a p53 in
  • sirtuin inhibitors e.g., a SIRT1 inhibitor and a SIRT2 inhibitor or a SIRT1 inhibitor and SIRT3 inhibitor, or a SIRT2 inhibitor and a SIRT3 inhibitor, or other combinations of sirtuin inhibitors as disclosed above, to achieve dual inhibition of the sirtuins.
  • SIRT1 inhibitors include EX-527 and (S)-35 as noted above, and HR73, having a structure
  • SIRT2 inhibitors include Ro31-8220 having a structure
  • sirtuin inhibitors contemplated include the following but specifically exclude suramin (see, e.g., Trapp, et al., Chem. Med. Chem., 2:1419-1431 (2007)):
  • sirtuin inhibitors include the following (see, e.g., Medda, et al., J. Med. Chem., 52:2673-2682 (2009)):
  • SIRT1 and SIRT2 inhibitors are the following (see, e.g., Napper, et al., J. Med. Chem., 48:8045-8054 (2005)):
  • sirtuin inhibitors having the following structures (see e.g. Bodner, et al., PNAS, 103(11):4246-4251 (2006) and Outeiro et al., Science, 317:516-519 (2007)):
  • sirtuin inhibitors having the following structures (see, e.g., Kiviranta, et al., J Med. Chem., 49(26):7907 (2006)):
  • sirtuin inhibitors as shown below (see, e.g., Sanders, et al., Bioorg. Med. Chem., 17(19):7031-7041 (2009)).
  • surfactin (7) (10) (11) (12) (13) (14a) (14b) Compound Hst2 IC 50 ( ⁇ M) SIRT1 IC 50 ( ⁇ M) Nicotinamide (1) 91 ⁇ 7 250 ⁇ 80 Sirtinol (2) 48 ⁇ 11 120 ⁇ 23 Splitomycin (3) >600 >500 Cambinol (4) >1000 >600 Tenovin-6 (5) >100* ⁇ 100* Ro 31-8220 (6) 20.0 ⁇ 0.9 25 ⁇ 7 Surfactin (7) >700 >600 Suramin (8) 240 ⁇ 70 0.6 ⁇ 0.3 Indole 35 (9) 1.3 ⁇ 0.1 0.18 ⁇ 0.02 Indole 2 (10) 14.5 ⁇ 0.6 0.64 ⁇ 0.06 11 6.5 ⁇ 1.3 6.0 ⁇ 0.4 12 19.9 ⁇ 0.6 80 ⁇ 5 13 12.5 ⁇ 0.6 34 ⁇ 10 14a 130 ⁇ 4 570 ⁇ 200 14b 260 ⁇ 20 nd
  • sirtuin inhibitors disclosed below (see, e.g., Schlicker, et al., Aging, 3(9):852 (2011)):
  • sirtuin inhibitors disclosed below (see, e.g., Yasuda, et al., Analytical Chem., 83:7400-7407 (2011)): quercetin and vitexin, as SIRT6 inhibitors.
  • sirtuin inhibitors disclosed below (see, e.g., Kalle, et al. Biochem. Biophys. Res. Comm., 401:13-19 (2010):
  • sirtuin inhibitors disclosed below (see, e.g., Asaba, et al., J. Am. Chem. Soc., 131:6989-6996 (2009)):
  • b Values are means ⁇ SD determined from at least three experiments.
  • d N.D. not determined., and in particular 2k.
  • sirtuin inhibitors as disclosed below (see, e.g., Gutierrez, et al., J. Org. Chem., 74:5267-5275 (2009)):
  • sirtuin inhibitors as disclosed below (see, e.g., Zhang, et al., Biochem. Biophys. Res. Comm., 386:729-733 (2009)):
  • sirtuin inhibitors as disclosed below (see, e.g., Huber, e t al., J. Med. Chem., 53:1383-1386 (2010)):
  • sirtuin(s) include the cyclic lipopeptide surfactin or derivatives thereof (see, Chakrabarty et al., Molec. Biochem. Parasitol., 158:139-151 (2008).
  • sirtuin(s) include microRNA, such as disclosed in, e.g., Gambari, et al., Biochem. Pharmacol., 82:1416-1429 (2011), Yamakuchi et al., PNAS, 105(36):13421-13426 (2008), Xu, et al., J. Cell. Biol., 193:409-124 (2011), or more specifically miR-34a, miR-22, or a derivative thereof as a sirtuin inhibitor.
  • microRNA such as disclosed in, e.g., Gambari, et al., Biochem. Pharmacol., 82:1416-1429 (2011), Yamakuchi et al., PNAS, 105(36):13421-13426 (2008), Xu, et al., J. Cell. Biol., 193:409-124 (2011), or more specifically miR-34a, miR-22, or a derivative thereof as a sirtuin inhibitor.
  • B2, AGK2, and BML-266 are each SIRT2 inhibitors.
  • EX-527 and (S)-35 are each SIRT1 inhibitors.
  • a SIRT2 inhibitor selected from B2, AGK2, BML-266, or combinations thereof are administered to B2, AGK2, BML-266, or combinations thereof and a SIRT1 inhibitor selected from EX-527, (S)-35, and combinations thereof.
  • p53 is at least partially responsible for the ability of dual SIRT1/SIRT2 inhibitors to block HCMV replication ( FIG. 6 ) and other sirtuins have been shown to alter the activity of p53 (see, e.g., Li et al., PLoS One 5, e10486, 2010), it is further contemplated that drugs inhibiting combinations of sirtuins in addition to SIRT1/SIRT2 dual inhibitors inhibit HCMV replication and the replication of other viruses that depend on the inactivation of p53.
  • these combinations of sirtuin inhibitors are disclosed herein as antiviral therapeutics.
  • the present disclosure includes methods of treating a viral infection by administering one or more inhibitors of two or more sirtuins.
  • contemplated are methods of administering inhibitors of multiple sirtuins and further administering one or more activators of one or more of the sirtuins that are not inhibited, or combinations of drugs that inhibit and activate different sirtuins.
  • contemplated are methods of treating a viral infection comprising administering a SIRT1 inhibitor, a SIRT2 inhibitor, and a SIRT3 activator (agonist) to subject in need thereof.
  • the present disclosure includes methods of treating HCMV infections using activators of any, a subset or all of seven sirtuins. Also provided is the use of therapeutics that simultaneously inhibit SIRT1 and SIRT2 (or, more generally, simultaneously inhibiting two or more sirtuins) to treat HCMV infections.
  • These inhibitors include without limitation small molecules, nucleic acids, proteins, and peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • siRNA screens were performed to test whether sirtuins also inhibit the replication of herpes simplex type 1 (HSV1), adenovirus (Ad5) and influenza A (Flu A) viruses. Each of these viruses generated elevated yields in response to knock down of multiple, individual siRNAs ( FIG. 7 ). This result leads to a conclusion that sirtuin activators will inhibit not only HCMV, but also herpes simplex viruses, adenoviruses and influenza viruses. Given the diversity of these viruses (both slow and fast growing; both RNA and DNA viruses), the results predict that sirtuin agonists will exhibit broad spectrum antiviral activity. Thus, the present disclosure includes the use of sirtuin agonists as broad spectrum antiviral therapeutics.
  • the dual inhibitors reduced virus replication to a greater extent than did oseltamivir (TamiFlu®) which was included as a comparator ( FIG. 8 ), and cambinol cooperated with oseltamivir to inhibit influenza A ( FIG. 9 ).
  • the dual inhibitors also blocked the production of adenovirus progeny ( FIG. 10 ).
  • dual SIRT1/SIRT2 inhibitors inhibit not only HCMV, but also influenza A and adenoviruses, making dual SIRT1/SIRT2 inhibitors broad spectrum antivirals that are useful for treatment as a single agent or in combination with other agents, as described further below.
  • Embodiments herein include methods of treating viral infections, including HCMV and adenovirus infections, using dual SIRT1 and 2 inhibitors (or more generally, inhibitors of two or more sirtuins), and optionally in combination with activators of another sirtuin.
  • These sirtuin modulators include without limitation small molecules, nucleic acids, proteins, and derivatives thereof. Additional small molecule activators and inhibitors can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Sirtuin agonists dual SIRT1 and SIRT2 inhibitors, and inhibitors of two or more sirtuins have utility as anti-viral drugs.
  • the work herein is the first to show that the yields of HCMV are induced by inhibition of individual sirtuins and therefore indicate that induction of sirtuin levels or activity or both would inhibit the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny. Modulation of each of the seven sirtuins can influence viral replication and therefore predict that induction of any one of the different known sirtuin activities will inhibit the production of HCMV progeny. These results also raise the possibility that induction of multiple sirtuins will synergistically inhibit the production of HCMV progeny. Importantly, simultaneous inhibition of SIRT1 and SIRT2 inhibits HCMV, in spite of the fact that inhibition of either separately increases virus yield.
  • Embodiments include inhibition of HCMV by agonists of one or more sirtuin (SIRT1-7), and the agonists. Some agonists may only target one sirtuin, but one or more agonists targeting multiple sirutins may also be provided.
  • An embodiment includes an agonist of one or more of the mitochondrial sirtuins (SIRT3-5), because the siRNA data reveals that modulation of SIRT3 and SIRT5 has the greatest effect on HCMV yield.
  • Embodiments include inhibition of a virus by antagonists of SIRT1 and SIRT2, or antagonists of two or more sirtuins (SIRT1-7), and the agents capable of causing the inhibition.
  • the virus may be HCMV.
  • the virus may be one that must inactivate p53 in order to produce an optimal yield of infectious progeny or maintain itself within an infected cell.
  • the virus may be any virus. Inhibition can be accomplished using drugs that inhibit both sirtuins or by using a combination of two drugs, one of which inhibits SIRT1 and the other of which inhibits SIRT2.
  • Embodiments include methods of treating viral infections.
  • Embodiments include methods of treating HCMV infections in human patients.
  • the methods include a step of administering agonists, or activators, of any sirtuin, agonists of a subset sirtuins or agonists all of seven sirtuins to a patient.
  • These agonists include without limitation at least one of small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Embodiments include methods of treating viral infections.
  • Embodiments include methods of treating HCMV infections in mammals, or more specifically human patients.
  • Embodiments include methods of treating viral infections where the virus requires p53 inactivation.
  • the methods include a step of administering antagonists of sirtuins, in particular antagonists of both SIRT1 and SIRT2 to a patient.
  • These antagonists include without limitation at least one of small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule antagonists can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Embodiments include anti-viral drugs that may be used for treating viral infections.
  • the anti-viral drugs may be agonists or antagonists of any sirtuin, agonists or antagonists of a subset sirtuins or agonists or antagonists all of seven sirtuins.
  • These activators include without limitation small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • methods that further comprise contacting a virus with a second agent, e.g., an anti-viral agent that is not the SIRT1 and SIRT2 inhibitors or the sirtuin agonist or a second agent that is a different SIRT1 and/or SIRT2 inhibitor or sirtuin agonist as disclosed herein.
  • a second agent e.g., an anti-viral agent that is not the SIRT1 and SIRT2 inhibitors or the sirtuin agonist or a second agent that is a different SIRT1 and/or SIRT2 inhibitor or sirtuin agonist as disclosed herein.
  • Contemplated second agents include, without limitation, acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, immunovir, idoxuridine, imiquimod, indinavir, inosine, integr
  • HCMV DNA, RNA and protein have been shown to be present in some human tumors, including malignant glioma (Cobbs CS. Herpesviridae 2:10, 2011), and the presence of the virus is thought to promote the pathogenesis of these cancers.
  • dual sirtuin antagonists or, more generally, by simultaneously inhibiting two or more sirtuins in patients with cancers, where at least a portion of the tumor cells (malignant tumor cells or tumor-associated stromal cells) contain the HCMV genome, is predicted to be therapeutically beneficial.
  • Dual sirtuin inhibitors could be used alone or in combination with other anti-viral or anti-tumor therapeutics.
  • a preferred embodiment of this therapeutic application of dual sirtuin inhibitors would be treatment of malignant glioma, but any tumor containing the HCMV genome in at least a portion of its cells is disclosed herein as a target for this therapy.
  • a second preferred embodiment of this therapeutic application would be treatment of tumors containing the genome of HCMV, but tumors with the genome any virus whose replication can be inhibited by dual sirtuin inhibitors, are disclosed herein as a target for this therapy.
  • a preferred therapeutic application comprises inhibitors of SIRT1 and SIRT2, inhibitors of SIRT1 plus SIRT2 plus another sirtuin, inhibitors of SIRT1 plus one or more sirtuins that do not include SIRT2, inhibitors of SIRT2 plus one or more sirtuins that do not include SIRT1, or a combination of inhibitors of two or more sirtuins that do not include SIRT1 or SIRT2.
  • Embodiments include a pharmaceutical composition including any of the anti-viral drugs herein and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier may include at least one of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, human serum albumin, buffer substances, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, waxes, polyethylene glycol, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, talc, magnesium carbonate, kaolin, non-ionic surfactants, edible oils, physiological saline, bacteriostatic
  • the route for administering a drug or pharmaceutical composition may be by any route.
  • the route of administration may be any one or more route including but not limited to oral, injection, topical, enteral, rectal, gastrointestinal, sublingual, sublabial, buccal, epidural, intracerebral, intracerebroventricular, intracisternal, epicutaneous, intradermal, subcutaneous, nasal, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intrathecal, intraperitoneal, intravesical, intravitreal, intracavernous, intravaginal, intrauterine, extra-amniotic, transdermal, intratumoral, and transmucosal.
  • Also disclosed herein are methods of increasing virus yield by inhibiting sirtuin activity e.g., inhibiting one or more of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7. Further contemplated are methods wherein neither SIRT1 nor SIRT2 are inhibited or only one of SIRT1 and SIRT2 are inhibited. In various cases, one or more of SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7 are inhibited.
  • results herein are the first to show that the yield of HCMV, herpes simplex virus, adenovirus, and influenza virus is induced by inhibition of sirtuins and therefore indicate that reduction of sirtuin protein levels or activity or both would enhance the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny and other viruses that are inhibited by sirtuin activity.
  • results herein are also the first to show that modulation of each of the seven sirtuins can influence viral replication and therefore provide a prediction that inhibition of any one of the different known sirtuin activities will enhance the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny.
  • additional viruses include but are not limited to: polio viruses, hepatitis A virus, rabies virus, measles virus, mumps virus, rubella virus, rotavirus, varicella zoster virus, yellow fever virus, lentiviruses including HIV, retroviruses and adeno-associated virus.
  • Inhibition of sirtuins to increase viral yields can be achieved by contacting a cell with an inhibitor of a sirtuin or inhibitor of sirtuin expression. Inhibition of sirtuin expression can be by RNAi, e.g., contacting one or more siRNA to one or more of the mRNAs encoding sirtuins. Specific siRNAs tested and shown in FIG. 1 are in Table 3.
  • Table 3A A subset of sequences from Table 3 contemplated for use as inhibitors of sirtuin gene expression and increase in virus production are shown in Table 3A, below. The use of these siRNAs and any other siRNA able to inhibit sirtuin expression is contemplated.
  • Inhibition of sirtuin expression can be by RNAi, e.g., contacting one or more shRNAs to one or more of the mRNAs encoding sirtuins. Sequences of shRNA for various sirtuin genes are shown in Table 4, below. The use of these shRNAs and any other shRNA able to inhibit sirtuin expression is contemplated.
  • musculus 46 CCGGAGTGAGACCAGTAGCACTAATCTCGAGATTAGTGCTACTGGTCTCACTTTTTTG 47 CCGGGCCATGTTTGATATTGAGTATCTCGAGATACTCAATATCAAACATGGCTTTTTG 48 CCGGGAGGGTAATCAATACCTGTTTCTCGAGAAACAGGTATTGATTACCCTCTTTTTG Sirt2 H.
  • Sapiens 49 CCGGTATGACAACCTAGAGAAGTACCTCGAGGTACTTCTCTAGGTTGTCATATTTTTG 50
  • CCGGCAGAAGACATTGCTTATTGGACTCGAGTCCAATAAGCAATGTCTTCTGTTTTTG 51 CCGGCCTGTGGCTAAGTAAACCATACTCGAGTATGGTTTACTTAGCCACAGGTTTTTG M.
  • musculus 64 GTACCGGAGTAAACCACAACTGTCTATGCTCGAGCATAGACAGTTGTGGTTTACTTTTTG 65 CCGGGCAGCATATCCGGAACCTTAACTCGAGTTAAGGTTCCGGATATGCTGCTTTTTG 66 CCGGTTGACTTTCAGGCCGACAAAGCTCGAGCTTTGTCGGCCTGAAAGTCAATTTTTG Sirt5 H.
  • musculus 70 CCGGGCAGACAATCTGTTACGTGATCTCGAGATCACGTAACAGATTGTCTGCTTTTTG 71 CCGGCCAGTTGTGTTGTAGACGAAACTCGAGTTTCGTCTACAACACAACTGGTTTTTG 72 CCGGCGACAGATTCAGGTTTCATTTCTCGAGAAATGAAACCTGAATCTGTCGTTTTTG Sirt6 H.
  • siRNA and shRNA that inhibit gene expression of any of the genes referenced in Table 5, as well as sirtuin genes from other species, are specifically contemplated.
  • RNA interference a post-transcriptional process triggered by the introduction of double-stranded RNA, leads to gene silencing in a sequence-specific manner.
  • double-stranded RNA dsRNA
  • dsRNA double-stranded RNA
  • the RNAi compounds are often referred to as short interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs).
  • RNAi compounds i.e., single- or double-stranded RNA or RNA-like compounds
  • RNase H-dependent antisense compounds bind to their RNA target by base pairing (i.e., hybridization) and induce site-specific cleavage of the target RNA by specific RNAses; i.e., both are antisense mechanisms (Vickers et al., 2003, J. Biol. Chem., 278, 7108-7118).
  • Double-stranded ribonucleases such as those in the RNase III and ribonuclease L family of enzymes also play a role in RNA target degradation. Double-stranded ribonucleases and oligomeric compounds that trigger them are further described in U.S. Pat. Nos. 5,898,031 and 6,107,094.
  • siRNAs or shRNAs in stably transfected mammalian cells
  • a mammalian cell in order to obtain long-term gene silencing, expression vectors that continually express siRNAs or shRNAs in stably transfected mammalian cells
  • Bolmmelkamp et al. Science 296: 550-553, 2002; Lee et al., Nature Biotechnol. 20:500-505, 2002; Miyagishi, M, and Taira, K. Nature Biotechnol. 20:497-500, 2002
  • Paul et al. Nature Biotechnol. 20:505-508, 2002
  • Sui Proc. Natl. Acad. Sci.
  • shRNAs lacking poly (A) tails. Transcription of shRNAs can be initiated at a polymerase III (pol III) promoter and is believed to be terminated at position 2 of a 4-5-thymine transcription termination site. Upon expression, shRNAs are thought to fold into a stem-loop structure with 3′ UU-overhangs. Subsequently, the ends of these shRNAs are processed, converting the shRNAs into ⁇ 21 nt siRNA-like molecules. The siRNA-like molecules can, in turn, bring about gene-specific silencing in the transfected mammalian cells.
  • poly III polymerase III
  • Interfering RNAs are therefore double stranded oligonucleotide agents that have complementarity to (i.e., are able to hybridize with) a portion of the target RNA (generally messenger RNA (mRNA)).
  • target RNA generally messenger RNA (mRNA)
  • mRNA messenger RNA
  • complementarity is 100%, but can be less if desired, such as about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 70%, about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% as long as conditions permit hybridization of the siRNA to the desired target.
  • oligonucleotide used in the methods need not be 100% complementary to a desired target nucleic acid in order for the siRNA to hybridize to the target.
  • oligonucleotides may hybridize to each other over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure).
  • Percent complementarity between any given oligonucleotide can be determined routinely using BLAST programs (Basic Local Alignment Search Tools) and PowerBLAST programs known in the art (Altschul et al., 1990, J. Mol. Biol., 215: 403-410; Zhang and Madden, 1997, Genome Res., 7: 649-656).
  • 100% complementarity to the target sequence is required in order to effectively discern the target sequence from the other non-target sequences.
  • choice of length is also an important factor because it is the other factor involved in the percent complementary and the ability to differentiate between target and n on-target sequences.
  • Hybridization means an interaction between two or three strands of nucleic acids by hydrogen bonds in accordance with the rules of Watson-Crick DNA complementarity, Hoogstein binding, or other sequence-specific binding known in the art. Hybridization can be performed under different stringency conditions known in the art.
  • RNA includes duplexes of two separate strands, as well as single, triple, or quadruple stranded structures.
  • An example of a single strand RNA is an RNA with a hairpin loop.
  • An inhibitory RNA sequence needs to be of sufficient length to bring the small interfering RNA and target RNA together through complementary base-pairing interactions.
  • the RNA useful in the methods disclosed herein may be of varying lengths.
  • RNA as disclosed herein, comprises a domain in a single strand of the duplex sufficiently complementary to a sequence in a target polynucleotide to permit hybridization of the single strand to the target polynucleotide under appropriate conditions, and hybridization of the single stranded domain of the duplex to the sequence in the target polynucleotide creates a substrate site recognized by a polypeptide.
  • the length of this single stranded domain is in some aspects greater than or equal to ten nucleotides and of sufficient length to hybridize with the target RNA; specifically 10-100 nucleotides; more specifically any integer between 10 and 80 nucleotides, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,
  • target or “target polynucleotide” refers to a polynucleotide against which a given RNA can be directed.
  • duplex refers to a region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary.
  • a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex” has 19 base pairs. The remaining bases may, for example, exist as 5′ and 3′ overhangs.
  • 100% complementarity is not required; substantial complementarity is allowable within a duplex.
  • Substantial complementarity refers to 75% or greater complementarity. For example, a mismatch in a duplex consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex substantially complementary.
  • RNA may be polymerized in vitro, recombinant RNA, contain chimeric sequences, or derivatives of these groups.
  • the RNA contains, in various embodiments, ribonucleotides, deoxyribonucleotides, synthetic nucleotides, or any suitable combination such that expression of the target gene is inhibited.
  • a delivered RNA can stay within the cytoplasm or nucleus.
  • the RNA can be delivered to a cell to inhibit expression of an endogenous or exogenous nucleotide sequence or protein or to affect a specific physiological characteristic not naturally associated with the cell.
  • RNA can be delivered to a cell in order to produce a cellular change that is therapeutic.
  • the delivery of RNA or other genetic material for therapeutic purposes is called gene therapy.
  • the RNA can be delivered either directly to the organism in situ or indirectly by transfer to a cell ex vivo that is then transplanted into the organism. Entry into the cell is required for the RNA to block the production of a protein or to decrease the amount of a RNA.
  • Polynucleotide sequences contemplated by the present disclosure are further described below.
  • nucleotide or its plural as used herein is interchangeable with modified forms as discussed herein and otherwise known in the art.
  • base which embraces naturally-occurring nucleotides as well as modifications of nucleotides that can be polymerized.
  • nucleotide or nucleobase means the naturally occurring nucleobases adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U) as well as non-naturally occurring nucleobases such as xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N′,N′-ethano-2,6-diaminopurine, 5-methylcytosine (mC), 5-(C 3 -C 6 )-alkynyl-cytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-tr-iazolopyridin, isocytosine, isoguanine, inosine and the “non-naturally occurring” nucleobases described in Benner et
  • nucleobase also includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof. Further naturally and non-naturally occurring nucleobases include those disclosed in U.S. Pat. No. 3,687,808 (Merigan, et al.), in Chapter 15 by Sanghvi, in Antisense Research and Application, Ed. S. T. Crooke and B.
  • polynucleotides also include one or more “nucleosidic bases” or “base units” which include compounds such as heterocyclic compounds that can serve like nucleobases, including certain “universal bases” that are not nucleosidic bases in the most classical sense but serve as nucleosidic bases.
  • Universal bases include 3-nitropyrrole, optionally substituted indoles (e.g., 5-nitroindole), and optionally substituted hypoxanthine.
  • Other desirable universal bases include, pyrrole, diazole or triazole derivatives, including those universal bases known in the art.
  • Polynucleotides may also include modified nucleobases.
  • a “modified base” is understood in the art to be one that can pair with a natural base (e.g., adenine, guanine, cytosine, uracil, and/or thymine) and/or can pair with a non-naturally occurring base.
  • exemplary modified bases are described in EP 1 072 679 and WO 97/12896, the disclosures of which are incorporated herein by reference.
  • Modified nucleobases include without limitation, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl
  • Further modified bases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g.
  • Modified bases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Additional nucleobases include those disclosed in U.S. Pat. No.
  • Certain of these bases are useful for increasing the binding affinity and include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are, in certain aspects combined with 2′-O-methoxyethyl sugar modifications. See, U.S. Pat. No. 3,687,808, U.S. Pat. Nos.
  • Modified polynucleotides are contemplated for functionalizing nanoparticles wherein both one or more sugar and/or one or more internucleotide linkage of the nucleotide units in the polynucleotide is replaced with “non-naturally occurring” groups.
  • this embodiment contemplates a peptide nucleic acid (PNA).
  • PNA compounds the sugar-backbone of a polynucleotide is replaced with an amide containing backbone. See, for example U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, and Nielsen et al., Science, 1991, 254, 1497-1500, the disclosures of which are herein incorporated by reference.
  • polynucleotides include those containing modified backbones or non-natural internucleoside linkages.
  • Polynucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone.
  • Modified polynucleotides that do not have a phosphorus atom in their internucleoside backbone are considered to be within the meaning of “polynucleotide.”
  • Modified polynucleotide backbones containing a phosphorus atom include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage.
  • polynucleotides having inverted polarity comprising a single 3′ to 3′ linkage at the 3′-most internucleotide linkage, i.e. a single inverted nucleoside residue which may be abasic (the nucleotide is missing or has a hydroxyl group in place thereof). Salts, mixed salts and free acid forms are also contemplated.
  • Modified polynucleotide backbones that do not include a phosphorus atom have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • polynucleotides are provided with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and including —CH 2 —NH—O—CH 2 —, —CH 2 —N(CH 3 )—O—CH 2 —, —CH 2 —O—N(CH 3 )—CH 2 —, —CH 2 —N(CH 3 )—N(CH 3 )—CH 2 — and —O—N(CH 3 )—CH 2 —CH 2 — described in U.S. Pat. Nos. 5,489,677, and 5,602,240. See, for example, U.S. Pat. Nos.
  • the linkage between two successive monomers in the oligo consists of 2 to 4, desirably 3, groups/atoms selected from —CH 2 —, —O—, —S—, —NRH—, >C ⁇ O, >C ⁇ NRH, >C ⁇ S, —Si(R′′) 2 —, —SO—, —S(O) 2 —, —P(O) 2 —, —PO(BH 3 )—, —P(O,S)—, —P(S) 2 —, —PO(R′′)—, —PO(OCH 3 )—, and —PO(NHRH)—, where RH is selected from hydrogen and C1-4-alkyl, and R′′ is selected from C 1-6 -alkyl and phenyl.
  • Modified polynucleotides may also contain one or more substituted sugar moieties.
  • polynucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C 1 to C 10 alkyl or C 2 to C 10 alkenyl and alkynyl.
  • polynucleotides comprise one of the following at the 2′ position: C1 to C10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2 CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a polynucleotide, or a group for improving the pharmacodynamic properties of a polynucleotide, and other substituents having similar properties.
  • a modification includes 2′-methoxyethoxy (2′-O—CH 2 CH 2 OCH 3 , also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., 1995, Helv. Chim. Acta, 78: 486-504) i.e., an alkoxyalkoxy group.
  • modifications include 2′-dimethylaminooxyethoxy, i.e., a O(CH 2 ) 2 ON(CH 3 ) 2 group, also known as 2′-DMAOE, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethyl-amino-ethoxy-ethyl or 2′-DMAEOE), i.e., 2′-O—CH 2 —O—CH 2 —N(CH 3 ) 2 .
  • Still other modifications include 2′-methoxy (2′-O—CH 3 ), 2′-aminopropoxy (2′-OCH 2 CH 2 CH 2 NH 2 ), 2′-allyl (2′-CH 2 —CH ⁇ CH 2 ), 2′-O-allyl (2′-O—CH 2 —CH ⁇ CH 2 ) and 2′-fluoro (2′-F).
  • the 2′-modification may be in the arabino (up) position or ribo (down) position.
  • a 2′-arabino modification is 2′-F.
  • polynucleotide Similar modifications may also be made at other positions on the polynucleotide, for example, at the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked polynucleotides and the 5′ position of 5′ terminal nucleotide.
  • Polynucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. See, for example, U.S. Pat. Nos.
  • a modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2′-hydroxyl group is linked to the 3′ or 4′ carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety.
  • the linkage is in certain aspects a methylene (—CH 2 —)n group bridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2.
  • LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226, the disclosures of which are incorporated herein by reference.
  • chimeric antisense compounds typically contain at least one region including a modification as described herein, while the remainder of the oligonucleotide remains “unmodified.”
  • the modification confers increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid.
  • the modification serves as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
  • RNAse H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression.
  • RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNAseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
  • Chimeric compounds may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. See, for example, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, the disclosures of which are incorporated herein by reference in their entireties.
  • the disclosure provides methods of targeting specific nucleic acids, e.g., specific RNAs coded by sirtuin genes as disclosed in Table 5.
  • the target nucleic acid may be in cells, tissue samples, or biological fluids, as also known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed. 1989) and B. D. Hames and S. J. Higgins, Eds., Gene Probes 1 (IRL Press, New York, 1995).
  • start codon region and “translation initiation codon region” refer to a portion of a mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon.
  • stop codon region and “translation termination codon region” refer to a portion of such a mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon.
  • start codon region (or “translation initiation codon region”) and the “stop codon region” (or “translation termination codon region”) are all regions which may be targeted effectively with the oligonucleotides on the functionalized nanoparticles.
  • target regions include the 5′ untranslated region (5′UTR), the portion of an mRNA in the 5′ direction from the translation initiation codon, including nucleotides between the 5′ cap site and the translation initiation codon of a mRNA (or corresponding nucleotides on the gene), and the 3′ untranslated region (3′UTR), the portion of a mRNA in the 3′ direction from the translation termination codon, including nucleotides between the translation termination codon and 3′ end of a mRNA (or corresponding nucleotides on the gene).
  • the 5′ cap site of a mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′-5′ triphosphate linkage.
  • the 5′ cap region of a mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap site.
  • dominant negative proteins can be used to inhibit sirtuin activity.
  • Dominant negative proteins are proteins that interfere with the activity of their normal counterparts. Dominant negative proteins no longer mediate all aspects of a protein's normal function, and also inhibit the normal functioning of the corresponding wild-type protein or the function of other proteins with which they interact. Dominant negative proteins can be introduced into cells by a variety of methods well known in the art.
  • Transgenic animals can be produced by methods well known in the art.
  • Various methods for directing mutations to specific targets within cells are well known in the art, e.g., by using engineered zinc-finger endonucleases (Sander et al., Nat Methods 8, 67-9, 2011) or by using TALENS (Cermak et al., Nucl Acids Res 39, e82).
  • references cited throughout this application are incorporated for all purposes apparent herein and in the references themselves as if each reference was fully set forth. For the sake of presentation, specific ones of these references are cited at particular locations herein. A citation of a reference at a particular location indicates a manner(s) in which the teachings of the reference are incorporated. However, a citation of a reference at a particular location does not limit the manner in which all of the teachings of the cited reference are incorporated for all purposes.
  • Paragraph 1 A composition comprising a one or more sirtuin agonist.
  • Paragraph 2 The composition of paragraph 1, wherein the one or more sirtuin agonist increases the activity of any, a subset of, or all of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 or SIRT7.
  • Paragraph 3 The composition of paragraph 1 or 2, wherein the one or more sirtuin agonist is selected from the group consisting of small molecules, nucleic acids, proteins, peptide based activators, CAY10602, Resveratrol, Quercetin, Butein, Piceatannol, Isoiquiritigenin, Fisetin, Pyrroloquinoxaline, Oxazolopyridine, SRT1720, SRT1460, SRT2379 and SRT2104.
  • the one or more sirtuin agonist is selected from the group consisting of small molecules, nucleic acids, proteins, peptide based activators, CAY10602, Resveratrol, Quercetin, Butein, Piceatannol, Isoiquiritigenin, Fisetin, Pyrroloquinoxaline, Oxazolopyridine, SRT1720, SRT1460, SRT2379 and SRT2104.
  • Paragraph 4 The composition of any of the preceding paragraphs, including any one or more of CAY10602, Resveratrol, Quercetin, Butein, Piceatannol, Isoiquiritigenin, Fisetin, Pyrroloquinoxaline, Oxazolopyridine, SRT1720, SRT1460, SRT2379 or SRT2104.
  • composition comprising a sirtuin gene expression activator.
  • composition comprising a sirtuin allosteric activator.
  • Paragraph 7 The composition of any of the preceding paragraphs, wherein the agonist includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; the expression activator includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; and the allosteric activator includes at least one of a small molecule, a nucleic acid, a protein, or a peptide.
  • Paragraph 8 A composition comprising at least one of a sirtuin agonist, a sirtuin gene expression activator, or a sirtuin activator of any of the preceding paragraphs.
  • Paragraph 9 A composition comprising one or more sirtuin antagonist.
  • Paragraph 10 The composition of paragraph 9 wherein the one or more sirtuin antagonists decreases the activity of both of SIRT1 and SIRT2.
  • Paragraph 11 The composition of paragraph 9 or 10 wherein the sirtuin antagonist is selected from the group consisting of small molecules, nucleic acids, proteins, peptide based activators alone or in combination with at least one of Cambinol, Tenovin 1, Tenovin 6, Salermide and Sirtinol.
  • composition comprising one or more sirtuin gene expression inhibitors.
  • Paragraph 13 A composition comprising one or more sirtuin competitive inhibitors.
  • Paragraph 14 The composition of any of paragraphs 9-13, wherein the antagonist includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; the expression inhibitor includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; and the competitive inhibitor includes at least one of a small molecule, a nucleic acid, a protein, or a peptide.
  • Paragraph 15 A composition comprising at least one of a sirtuin antagonist, a sirtuin gene expression inhibitor, or a sirtuin competitive inhibitor of any of the preceding paragraphs.
  • Paragraph 16 A pharmaceutical composition comprising the composition of any of paragraphs 1-15 and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier includes at least one substance selected from the group consisting of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, human serum albumin, buffer substances, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, waxes, polyethylene glycol, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, talc, magnesium carbonate, kaolin, non-ionic surfactants, edible oils, physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parophor ELTM (BASF, Par
  • Paragraph 18 A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient.
  • Paragraph 19 A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by any one or more virus.
  • Paragraph 20 A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by a single virus.
  • Paragraph 21 A method of treating disease comprising providing the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by HCMV.
  • Paragraph 22 A method of treating disease comprising induction of sirtuin gene expression in a patient.
  • Paragraph 23 A method of treating disease comprising inhibition of sirtuin gene expression in a patient.
  • Paragraph 24 The method of paragraph 22 or 23, wherein the expression of any one or more of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 or SIRT7 is induced or inhibited, respectively.
  • Paragraph 25 A method of inhibiting virus production comprising contacting the virus with a sirtuin agonist.
  • Paragraph 26 The method of paragraph 25, wherein the sirtuin agonist is a polyhydroxy chalcone, polyhydroxy flavonoid, polyhydroxy stilbene, or a combination thereof.
  • Paragraph 27 The method of paragraph 25, wherein the agonist has a structure
  • R 1 is H or OH and R 2 is
  • R 2 is H or OH
  • the dashed line indicates an optional double bond
  • x and y are each 0, 1, 2, 3, 4, or 5, and x+y ⁇ 1
  • w and z are each 0, 1, 2, 3, 4, or 5, and w+z ⁇ 1
  • n and m are each 0, 1, 2, 3, 4, or 5, n+m ⁇ 1, or a salt or ester thereof.
  • Paragraph 28 The method of paragraph 27, wherein the dashed line is a double bond.
  • Paragraph 29 The method of paragraph 27 or 28, wherein R 1 is H or OH and R 2 is
  • Paragraph 30 The method of paragraph 27 or 28, wherein R 2 is H or OH and R 1 is
  • Paragraph 31 The method of paragraph 25, wherein the sirtuin agonist is resveratrol, quercetin, rutin, butein, piceatannol, isoliquiritigenin, fisetin, fustin, sulfuretin, genistein, daidzein, taxifolin, aromadedrin, a combination thereof, or a salt or ester thereof.
  • the sirtuin agonist is resveratrol, quercetin, rutin, butein, piceatannol, isoliquiritigenin, fisetin, fustin, sulfuretin, genistein, daidzein, taxifolin, aromadedrin, a combination thereof, or a salt or ester thereof.
  • Paragraph 32 The method of paragraph 25, wherein the sirtuin agonist is CAY10602, pyrroloquinoxaline, oxazolopyridine, SRT1720, SRT1460, SRT2379, SRT2104, or GSK184072.
  • Paragraph 33 The method of paragraph 25, wherein the sirtuin agonist is 3,5-dihydroxy-4′-chloro-trans-stilbene, dipyridamole, 3,5-dihydroxy-4′ethyl-trans-stilbene, 3,5-dihydroxy-4′-isopropyl-trans-stilbene, 3,5-dihydroxy-4′-methyl-trans-stilbene, resveratrol, 3,5-dihydroxy-4′thiomethyl-trans-stilbene, 3,5-dihydroxy-4′-carbomethoxy-trans-stilbene, isoliquiritgenin, 3,5-dihydro-4′nitro-trans-stilbene, 3,5-dihydroxy-4′azido-trans-stilbene, piceatannol, 3-methoxy-5-hydroxy-4′acetamido-trans-stilbene, 3,5-dihydroxy-4′acetoxy-trans-stilbene, pinosylvin, fisetin, (E)-1-(3,5-dihydrophenyl)-2-(4-pyridy
  • Paragraph 34 The method of paragraph 25, wherein the sirtuin agonist is trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyfla
  • Paragraph 35 The method of any one of paragraphs 25-34, wherein the sirtuin is SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, or a combination thereof.
  • Paragraph 36 The method of any one of paragraphs 25-35, wherein the agonist activates only one sirtuin.
  • Paragraph 37 The method of any one of paragraphs 25-36, wherein the contacting comprising administering the agonist to a subject suffering from a viral infection.
  • Paragraph 38 The method of paragraph 37, wherein the subject is human.
  • Paragraph 39 The method of any one of paragraphs 25-38, wherein the virus is HCMV.
  • Paragraph 40 A method of inhibiting virus production comprising contacting the virus with a SIRT1/SIRT2 dual inhibitor.
  • Paragraph 41 The method of paragraph 40, wherein the SIRT1/SIRT2 dual inhibitor is cambinol, salermide, tenovin-6, tenovin-1, or a combination thereof.
  • Paragraph 42 The method of paragraph 40 or 41, wherein the virus inactivates p53 during viral replication.
  • Paragraph 43 The method of any one of paragraphs 40-42, wherein the virus is HCMV.
  • Paragraph 44 The method of any one of paragraphs 40-42, wherein the virus is human papilloma virus, HSV1, Ad5, FluA, human adenovirus, hepatitis B virus, hepatitis C virus, or HIV.
  • Paragraph 45 The method of any one of paragraphs 40-42, wherein the virus is Adenoviridae (Adenovirus, with E1B-55K as a p53 inactivating protein); Hepadnaviridae (HBV, with X protein as a p53 inactivating protein); Herpesviridae (EBV, with LMP1 as a p53 inactivating protein; HSV-1 with ICP0 as a p53 inactivating protein; HCMV, with IE1 as a p53 inactivating protein; KSHV with LANA as a p53 inactivating protein); Flaviviridae (HCV with NS5A as a p53 inactivating protein); Orthomixoviridae (Influenza A with NS1 as a p53 inactivating protein); Papillomaviridae (HPV with E6 as a p53 inactivating protein); Polyomaviridae (SV40 with Large T-antigen as a
  • Paragraph 46 The method of any one of paragraphs 25-45, further comprising contacting the virus with a second agent.
  • Paragraph 47 The method of paragraph 46, wherein the second agent is a second SIRT1/SIRT2 dual inhibitor or a second sirtuin agonist.
  • Paragraph 48 The method of paragraph 46, wherein the second agent is an antiviral agent.
  • Paragraph 49 The method of paragraph 48, wherein the antiviral agent is acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, immunovir, idoxuridine, imiquimod, indinavir,

Abstract

Agents and methods of inhibiting or improving the growth of viruses are provided.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The benefit of U.S. Provisional Application No. 61/438,846, filed Feb. 2, 2011, and U.S. Provisional Application No. 61/527,102, filed Aug. 24, 2011 is claimed, the disclosures of which are incorporated by reference in their entirety.
    • STATEMENT OF U.S. GOVERNMENT INTEREST
  • This invention was made with government support under grant numbers CA85786 and DP1DA026192, each awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.
    • BACKGROUND
  • Humans express seven sirtuins, termed SIRT1-7, all of which contain a conserved central NAD+-binding and catalytic domain. Sirtuins are NAD+-dependent deacetylases and ADP-ribosyltransferases. Sirtuins deacetylate acyl-lysine residues of histones and other proteins. Given their requirement for NAD+, sirtuins are regulated by the pathways that produce the cofactor, and, as a result, are responsive to the metabolic state of cells. While their expression profiles can vary, sirtuins are ubiquitously expressed in a wide range of tissues. Sirtuins are found in different cellular compartments: SIRT1, 6 and 7 are predominantly nuclear; SIRT3-5 are mitochondrial; and SIRT2 is a predominantly cytoplasmic resident. Drugs that activate sirtuins, such as resveratrol, appear to be well tolerated.
  • There have been several reports relating to the effects of resveratrol and SIRT1 on viruses or expression from viral promoters. For example: Resveratrol has been reported to inhibit varicella zoster virus replication in cultured cells (Docherty et al., 2006, Antiviral Res 72, 171-7); Resveratrol or overexpression of SIRT1 have been reported to inhibit the transactivation of the HIV-1 LTR in a transfection assay performed in cultured cells (Zhang et al., 2009, Life Sciences 85, 484-9); Resveratrol, SRT1720 or overexpression of SIRT1 have been reported to inhibit transgene expression from a replication-defective adenovirus in cultured neuronal cells (Picchione and Bhattacharjee, 2011, J Neurovirol, 17, 184-8); and HIV-1 Tat protein has been shown to negatively regulate SIRT1 (Kwon et al., 2008, Cell Host Microbe 3, 158-67).
    • SUMMARY
  • In an aspect, the invention relates to a composition comprising a one or more sirtuin agonists. Sirtuin agonists can be polyhydroxy stilbene compounds, polyhydroxy flavonoids (e.g., flavones, flavonols, isoflavones, or the like), polyhydroxy chalcone compounds, or combinations thereof. Specific examples of contemplated agonists include:
  • Figure US20130338178A1-20131219-C00001
  • wherein x and y are each 0, 1, 2, 3, 4, or 5, and x+y≧1;
  • Figure US20130338178A1-20131219-C00002
  • wherein w and z are each 0, 1, 2, 3, 4, or 5, and w+z≧1;
  • Figure US20130338178A1-20131219-C00003
  • wherein R1 is H or OH and R2 is
  • Figure US20130338178A1-20131219-C00004
    • or R1 is
  • Figure US20130338178A1-20131219-C00005
  • and R2 is H or OH; n and m are each 0, 1, 2, 3, 4, or 5, n+m≧1, and the dashed line indicates an optional double bond. Also specifically contemplated are sirtuin 5 agonists, such as 3,5-dihydroxy-4′-chloro-trans-stilbene, dipyridamole, 3,5-dihydroxy-4′ethyl-trans-stilbene, 3,5-dihydroxy-4′-isopropyl-trans-stilbene, 3,5-dihydroxy-4′-methyl-trans-stilbene, resveratrol, 3,5-dihydroxy-4′thiomethyl-trans-stilbene, 3,5-dihydroxy-4′-carbomethoxy-trans-stilbene, isoliquiritgenin, 3,5-dihydro-4′nitro-trans-stilbene, 3,5-dihydroxy-4′azido-trans-stilbene, piceatannol, 3-methoxy-5-hydroxy-4′acetamido-trans-stilbene, 3,5-dihydroxy-4′acetoxy-trans-stilbene, pinosylvin, fisetin, (E)-1-(3,5-dihydrophenyl)-2-(4-pyridyl)ethene, (E)-1-(3,5-dihydrophenyl)-2-(2-napthyl)ethene, 3,5-dihydroxy-4′-acetamide-trans-stilbene, butein, quercetin, 3,5-dihydroxy-4′-thioethyl-trans-stilbene), 3,5-dihydroxy-4′carboxy-trans-stilbene, and/or 3,4′-dihydroxy-5-acetoxy-trans-stilbene. Such agonists are described in US Patent Publication No. 2006/0014705, incorporated by reference in its entirety.
  • In an aspect, the invention relates to a composition comprising one or more sirtuin antagonists, or two or more sirtuin antagonists. Specifically contemplated SIRT1/SIRT2 dual inhibitors include cambinol, tenovin 1, tenovin 6, salermide, sirtinol, and combinations thereof. Also contemplated are compositions comprising a SIRT1 inhibitor and a SIRT2 inhibitor. Further contemplated are compositions comprising a SIRT1 inhibitor and one or more of the group comprising a SIRT2 inhibitor, a SIRT3 inhibitor, a SIRT4 inhibitor, a SIRT5 inhibitor, a SIRT6 inhibitor, and a SIRT7 inhibitor. SIRT inhibitors are readily identified through a screening assay.
  • In one aspect, disclosed herein are methods of inhibiting both SIRT1 and SIRT2 comprising contacting both SIRT1 and SIRT2 with one or more antagonist compounds. In various cases, the antagonist (e.g., a SIRT1/SIRT2 dual inhibitor or a SIRT1 inhibitor and a SIRT2 inhibitor) is cambinol, tenovin 1, tenovin 6, salermide, sirtinol, or combinations thereof, or is one or more compounds as detailed below. Further disclosed is a method of inhibiting virus production comprising contacting a virus-infected cell with a SIRT1/SIRT2 dual inhibitor or a combination of a SIRT1 inhibitor and a SIRT2 inhibitor.
  • Further disclosed are methods of inhibiting virus production comprising contacting a virus-infected cell with one or more inhibitors of two or more sirtuins, e.g., inhibiting SIRT1 and SIRT2; SIRT1 and SIRT3; SIRT1 and SIRT4; SIRT1 and SIRT5; SIRT1 and SIRT6; SIRT1 and SIRT7; SIRT2 and SIRT3; SIRT2 and SIRT4; SIRT2 and SIRT5; SIRT2 and SIRT6; SIRT2 and SIRT7; SIRT3 and SIRT4; SIRT3 and SIRT5; SIRT3 and SIRT6; SIRT3 and SIRT7; SIRT4 and SIRT5; SIRT4 and SIRT6; SIRT4 and SIRT7; SIRT5 and SIRT6; SIRT5 and SIRT7; and SIRT6 and SIRT7. Also disclosed are methods of inhibiting three or more sirtuins (e.g., non-limiting examples include inhibiting SIRT1, SIRT2, and SIRT3; inhibiting SIRT1, SIRT2, and SIRT5; and inhibiting SIRT1, SIRT3, and SIRT5). The inhibitors can be the same, or can be different (e.g., an inhibitor to both SIRT2 and SIRT3 or a SIRT2 inhibitor and a SIRT3 inhibitor). Also contemplated are methods of inhibiting virus production comprising containing a virus-infected cell with one or more inhibitors of three or more sirtuins.
  • In an aspect, the invention relates to a composition comprising one or more sirtuin antagonists that decreases the activity of both or each of SIRT1 and SIRT2. In some cases, the composition comprises a first compound that is a SIRT1 antagonist and a second compound that is a SIRT2 antagonist. Further disclosed are compositions comprising inhibitors of two or more sirtuins, e.g., inhibiting SIRT1 and SIRT2; SIRT1 and SIRT3; SIRT1 and SIRT4; SIRT1 and SIRT5; SIRT1 and SIRT6; SIRT1 and SIRT7; SIRT2 and SIRT3; SIRT2 and SIRT4; SIRT2 and SIRT5; SIRT2 and SIRT6; SIRT2 and SIRT7; SIRT3 and SIRT4; SIRT3 and SIRT5; SIRT3 and SIRT6; SIRT3 and SIRT7; SIRT4 and SIRT5; SIRT4 and SIRT6; SIRT4 and SIRT7; SIRT5 and SIRT6; SIRT5 and SIRT7; and SIRT6 and SIRT7. Also specifically disclosed are compositions comprising inhibitors of three or more sirtuins (e.g., non-limiting examples include SIRT1, SIRT2, and SIRT3 inhibitors; SIRT1, SIRT2, and SIRT5 inhibitors; and SIRT1, SIRT3, and SIRT5 inhibitors). The inhibitors can be the same, or can be different (e.g., an inhibitor to both SIRT2 and SIRT3 or a SIRT2 inhibitor and a SIRT3 inhibitor).
  • In an aspect, the invention relates to a pharmaceutical composition including any of the compositions herein and a pharmaceutically acceptable carrier.
  • In an aspect, the invention relates to a method of treating disease comprising administering any of the compositions or pharmaceutical compositions herein to a patient, e.g., a patient suffering from a viral infection or a disorder associated with a viral infection.
    • BRIEF DESCRIPTION OF THE FIGURES
  • The following detailed description of the preferred embodiments of the present invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It is understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown. In the drawings:
  • FIG. 1 illustrates that inhibition of sirtuins enhances the production of infectious human cytomegalovirus (HCMV) progeny.
  • FIG. 2 illustrates that the siRNAs used effectively reduced the levels of target sirtuin RNAs.
  • FIG. 3 illustrates that sirtuin agonists inhibit the production of infectious HCMV progeny.
  • FIG. 4 illustrates that a SIRT1 antagonist elevates the production of infectious virus, whereas an antagonist of both SIRT1 and SIRT2 inhibits the production of infectious HCMV progeny.
  • FIG. 5 illustrates that SIRT1/SIRT2 dual inhibitors tenovin-6 (left panel) and salermide (right panel) inhibit production of HCMV.
  • FIG. 6 illustrates that inhibition of HCMV replication by a dual SIRT1/SIRT2 inhibitor (Salermide) requires p53. Right panel: MRC5 cells stably expressing either p53 shRNA (shp53 MRC5) or non-targeting shRNA (NT MRC5) were infected with AD169 HCMV strain at a multiplicity of 0.5 IU/cell. At 2hpi, cells were treated either with 50 μM Salermide in DMSO or DMSO alone. This treatment was repeated at 48hpi. At 96hpi, virus-containing supernatants were collected and HCMV titers determined using infectious center assay in MRC5 cells. The result is representative of biological duplicates. Left panel: The knockdown of p53 in shp53 cell line was verified by Western Blot.
  • FIG. 7 illustrates that inhibition of sirtuins enhances the production of infectious herpes simplex virus type 1 (HSV1), adenovirus type 5 (Ad5) and influenza A (Flu A) progeny. MRC5 fibroblasts were transfected with siRNAs (the most robust siRNAs based on their activity in the HCMV assay) targeting each of the seven sirtuins. 72 h later, cells were infected with: top panel, HSV1 KOS strain at a multiplicity of 1 infectious unit per cell, and after an additional 22 h supernatants were collected and virus yields were determined by infectious center assay in MRC5 cells; middle panel, Ad5 at a multiplicity of 5 infectious units per cell, and after an additional 72 h, supernatants were collected and virus yields were determined by infectious center assay in HeLa cells; bottom panel, influenza WSN/33/A strain at a multipicity of 0.5 infectious unit per cell and after an additional 22 h supernatants were collected and virus yields were determined by TCID50 assay in MDCK cells.
  • FIG. 8 illustrates dual Sirt1/Sirt2 inhibitors, Cambinol and Salermide, block the production of infectious Influenza A progeny. MRC5 fibroblasts and MDCK cells were infected with the influenza WSN/33/A strain at a multiplicity of 0.01 TCID50/cell or PR8 strain at 0.1 TCID50/cell. The medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 1 hpi, and the yield of influenza A was determined at 24 hpi by standard TCID50 method on MDCK cells. The marketed neuraminidase inhibitor, oseltamivir (TamiFlu®), was used as a comparator for the efficacy of tested compounds in the assay.
  • FIG. 9 illustrates that the dual Sirt1/Sirt2 inhibitor, Cambinol, cooperates with oseltamivir to block the production of infectious Influenza A progeny. MDCK cells were infected with the influenza WSN/33/A strain at a multiplicity of 0.001 TCID50/cell. The medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 1 hpi, and the yield of influenza A was determined at 24 hpi by standard TCID50 method on MDCK cells.
  • FIG. 10 illustrates that a SIRT1 antagonist enhances the production of infectious adenovirus (Ad5) progeny, but dual SIRT1/SIRT2 antagonists block the production of progeny. MRC5 fibroblasts were infected with Ad5 at a multiplicity of 5 IU/cell. The medium of the cells was replaced with fresh medium containing the solvent (DMSO) or drugs dissolved in solvents at 2 hpi, and the yield of Ad5 was determined at 72 hpi.
    •  DETAILED DESCRIPTION
  • Certain terminology is used in the following description for convenience only and is not limiting. The words “right,” “left,” “top,” and “bottom” designate directions in the drawings to which reference is made.
  • The words “a” and “one,” as used in the claims and in the corresponding portions of the specification, are defined as including one or more of the referenced item unless specifically stated otherwise. This terminology includes the words above specifically mentioned, derivatives thereof, and words of similar import. The phrase “at least one” followed by a list of two or more items, such as “A, B, or C,” means any individual one of A, B or C as well as any combination thereof.
  • Referring to FIG. 1, MRC5 fibroblasts were transfected with three different siRNAs targeting each of the seven sirtuins. 24 hours later, cells were infected with the HCMV AD169 strain at a multiplicity of 0.5 IU/cell, and the yield of HCMV was determined at 96 hpi. Sample 1 (left bar above each siRNA label) and sample 2 (right bar above each siRNA label) represent two independent knockdown experiments. As illustrated, siRNA-mediated inhibition of each of the seven sirtuins augments the production of HCMV progeny in cultured fibroblasts.
  • Referring to FIG. 2, MRC5 cells were transfected with the indicated siRNAs; 24 hours later, cells were infected with the HCMV AD169 strain at a multiplicity of 0.5 IU/cell, and at 72 hpi the levels of sirtuin RNAs was determined by quantitative RT-qPCR by using GAPDH as the comparator. The level of knockdown induced by the siRNA that caused the greatest increase in virus yield for each sirtuin was monitored by quantitative RT-PCR, and each of the siRNAs proved to reduce the level of the targeted RNA.
  • Referring to FIG. 3, MRC5 fibroblasts were infected with an HCMV variant expressing GFP tagged pUL99 (the product of late viral UL99 gene) at a multiplicity of 0.25 IU/cell. Four hours after infection cells were treated with the indicated concentrations of resveratrol, CAY10602 or the carrier in which the drugs were dissolved (ethanol or DMSO). Virus yield at 96 h after infection was determined by infecting fibroblasts and assaying IE1 expression by immunofluorescence 24 h later. Treatment with 100 μM resveratrol or 25 μM CAY10602 reduced the virus yield to below the limit of detection (<102 IU/ml).
  • Referring to FIG. 4, MRC5 fibroblasts were infected with an HCMV variant expressing GFP tagged pUL99 (the product of late viral UL99 gene) at a multiplicity of 0.25 IU/cell. Two hours after infection cells were treated with the indicated concentrations of SIRT1 inhibitor, EX-527; the dual SIRT1 and 2 inhibitor, Cambinol, or the carrier in which the drugs were dissolved (DMSO). Virus yield at 96 h after infection was determined by infecting fibroblasts and assaying IE1 expression by immunofluorescence 24 h later. Treatment with 50 μM cambinol reduced the virus yield to below the limit of detection (<102 IU/ml).
  • These results demonstrate that all members of the sirtuin family inhibit HCMV replication, and they strongly predict that drugs that increase the activity of sirtuins (sirtuin agonists) will have anti-HCMV activity. The most prominent effects on HCMV replication were observed when the mitochondrial sirtuins, SIRT3, SIRT4, and SIRT5, were inhibited by siRNAs (FIG. 1). These enzymes modulate key factors responsible for central carbon metabolism. For instance, glutamate dehydrogenase, which directs glutamine flux to the tricarboxylic acid (TCA) cycle by converting it to α-ketoglutarate, is targeted by SIRT3 and 4. Of note, glutamine is the major carbon source feeding the TCA cycle in HCMV infected cells and essential for HCMV replication. These results indicate that activators of mitochondrial sirtuins are preferential targets for antiviral therapy.
  • Activation of one or more sirtuins is an embodiment. Activation of one or more mitochondrial sirtuins is an embodiment. A compound that increases sirtuin activity is referred to as a sirtuin agonist herein. The compound can be a small molecule, nucleic acid, protein, or peptide. Specific sirtuin agonists contemplated include stilbene, flavone, isoflavone, flavanone, catechin, free radical protective compound, isonicotinamide, dipyridamole, ZM 336372 (3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamide), camptothecin, coumestrol, nordihydroguaiaretic acid, esculetin, SRT-1720 (Sirtris), SRT-1460 (Sirtris), SRT-2183 (Sirtris), analogs thereof, or combinations thereof.
  • In some embodiments, the sirtuin agonist is a stilbene. In some embodiments, the stilbene is trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, or combinations thereof.
  • In some embodiments, the agonist is a chalcone. In some embodiments, the chalcone is chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; or combinations thereof.
  • In some embodiments, the agonist is a flavone. In some embodiments, the flavone is flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyflavone; 7,4′-dihydroxyflavone; 7,8,3′,4′-tetrahydroxyflavone; 3,6,2′,3′-tetrahydroxyflavone; 4′-hydroxyflavone; 5-hydroxyflavone; 5,4′-dihydroxyflavone; 5,7-dihydroxyflavone; or combinations thereof.
  • In some embodiments, the agonist is an isoflavone. In some embodiments, the isoflavone is daidzein, genistein, or combinations thereof.
  • In some embodiments, the agonist is a flavanone. In some embodiments, the flavanone is naringenin; flavanone; 3,5,7,3′,4′-pentahydroxyflavanone; or combinations thereof.
  • In some embodiments, the agonist is an anthocyanidin. In some embodiments, the anthocyanidin is pelargonidin chloride, cyanidin chloride, delphinidin chloride, or combinations thereof.
  • In some embodiments, the agonist is a catechin. In some embodiments, the catechin is (−)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-gallocatechin (Hydroxy Sites: 3,5,7,3′,4′,5′) (+)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (+)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); or combinations thereof.
  • In some embodiments, the agonist is a free radical protective compound. In some embodiments, the free radical protective compound is Hinokitiol (b-Thujaplicin; 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one); L-(+)-Ergothioneine ((S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole4-ethanam-inium inner salt); Caffeic Acid Phenyl Ester; MC1-186 (3-Methyl-1-phenyl-2-pyrazolin-5-one); HBED (N,N′-Di-(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid H2O); Ambroxol (trans-4-(2-Amino-3,5-dibromobenzylamino)cyclohexane-HC; and U-83836E ((−)-2-((4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperzainyl)m-ethyl)-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol 2HCl); or combinations thereof.
  • In some embodiments, the agonist is isonicotinamide or an analog of isonicotinamide. In some embodiments, the analog of isonicotinamide is .beta.-1′-5-methyl-nicotinamide-2′-deoxyribose; .beta.-D-1′-5-methyl-nico-tinamide-2′-deoxyribofuranoside; .beta.-1′-4,5-dimethyl-nicotinamide-2′-de-oxyribose; or .beta.-D-1′-4,5-dimethyl-nicotinamide-2′-deoxyribofuranoside. For additional analogs of isonicotinamide see U.S. Pat. Nos. 5,985,848; 6,066,722; 6,228,847; 6,492,347; 6,803,455; and U.S. Patent Publication Nos. 2001/0019823; 2002/0061898; 2002/0132783; 2003/0149261; 2003/0229033; 2003/0096830; 2004/0053944; 2004/0110772; and 2004/0181063, which are hereby incorporated by reference for that disclosure.
  • Further examples of sirtuin agonists include trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyflavone; 7,4′-dihydroxyflavone; 7,8,3′,4′-tetrahydroxyflavone; 3,6,2′,3′-tetrahydroxyflavone; 4′-hydroxyflavone; 5-hydroxyflavone; 5,4′-dihydroxyflavone; 5,7-dihydroxyflavone; daidzein, genistein, naringenin; flavanone; 3,5,7,3′,4′-pentahydroxyflavanone; pelargonidin chloride, cyanidin chloride, delphinidin chloride, (−)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-gallocatechin (Hydroxy Sites: 3,5,7,3′,4′,5′) (+)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (+)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); Hinokitiol (b-Thujaplicin; 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one); L-(+)-Ergothioneine ((S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethanam-inium inner salt); Caffeic Acid Phenyl Ester; MC1-186 (3-Methyl-1-phenyl-2-pyrazolin-5-one); HBED (N,N′-Di-(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid.H2O); Ambroxol (trans-4-(2-Amino-3,5-dibromobenzylamino)cyclohexane-HCl; and U-83836E ((−)-2-((4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperzainyl)m-ethyl)-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol.2HCl); .beta.-1′-5-methyl-nicotinamide-2′-deoxyribose; .beta.-D-1′-5-methyl-nico-tinamide-2′-deoxyribofuranoside; .beta.-1′-4,5-dimethyl-nicotinamide-2′-de-oxyribose; or .beta.-D-1′-4,5-dimethyl-nicotinamide-2′-deoxyribofuranoside; dipyridamole, ZM 336372 (3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-met hylphenyl]benzamide), camptothecin, coumestrol, nordihydroguaiaretic acid, esculetin, SRT-1720 (Sirtris), SRT-1460 (Sirtris), SRT-2183 (Sirtris), analogs thereof, or combinations thereof.
  • To further investigate the importance of sirtuins as anti-HCMV targets, the effect of known sirtuin activating compounds on HCMV replication was assayed. A variety of such small molecule SIRT1 activating compounds (STACs) have been described in the literature (for a review see Camins et al., 2010, Biochimica et Biophysica Acta 1799, 740-9, which is incorporated herein by reference as if fully set forth, (Table 1, below). In addition to the compounds listed in Table 1, dihydropyridine and imidazol-[1,2-b]thiazole derivatives have been recently identified as novel SIRT1 agonists (Mia et al., 2009, J. Med Chem., 52, 5496-504, which is incorporated herein by reference as if fully set forth). SRT1720 has a structure of
  • Figure US20130338178A1-20131219-C00006
  • SRT1460 has a structure of
  • Figure US20130338178A1-20131219-C00007
  • TABLE 1
    Compounds that increase the activity of sirtuins
    Compounds of
    natural origin EC1.5 Synthetic compounds EC1.5
    Resveratrol 46 μM Pyrroloquinoxaline   10 μM*
    Quercetin Oxazolopyridine 0.09 μM
    Butein SRT1720 0.16 μM
    Piceatannol SRT1460  2.9 μM
    Isoliquiritigenin SRT2379 0.36 μM
    Fisetin SRT2104
    GSK184072
    EC1.5: The concentration to activate 1.5-fold
    *233% activation at this concentration
  • Resveratrol, which is a polyphenol naturally found in some plants, is perhaps the best studied SIRT1 agonist. It increases SIRT1 activity by 1.5 fold at 46 μM and by 13 fold at 100 μM concentration (Howitz et al., 2003, Nature 425, 191-6). Resveratrol is selective for SIRT1 since it does not activate SIRT2 at 100 μM. To evaluate its effect on HCMV replication the compound was added to the culture medium of HCMV infected MRC5 cells containing 10% fetal calf serum at 4 hours after infection. Resveratrol inhibited cytopathic effect of HCMV and expression of late viral pUL99 was substantially reduced in a dose dependent manner (data not shown). The compound reduced the yield of infectious HCMV by a factor of >18-fold at 50 μM and >100-fold at 100 μM (FIG. 3).
  • Resveratrol has been reported to inhibit HCMV replication previously (Evers et al., 2004, Antiviral Res 63, 85-95. In particular, it was concluded that Resveratrol only inhibited viral attachment and entry. In contrast, the work herein is the first to show that modulation of each of the seven sirtuins, including SIRT1 (a principal target of resveratrol), can influence viral replication and therefore predict that induction any one of the different known sirtuin activities will inhibit the production of HCMV progeny.
  • The antiviral effect of SIRT1 activation on HCMV was further confirmed by employing a second SIRT1-activating compound, CAY10602, which has a structure:
  • Figure US20130338178A1-20131219-C00008
  • and is structurally distinct from resveratrol. CAY10602 was identified in a high-throughput screen as a compound that increases SIRT1-mediated deacetylation of a SIRT1-specific substrate and is a highly potent activator of SIRT1. It suppresses tumor necrosis factor alpha (TNFα) release, a process which is linked to the activity of SIRT1, to a 10-fold greater extent than resveratrol. In line with this, CAY10602 showed a strong anti-HCMV effect. At 25 μM, CAY10602 almost completely inhibited pUL99 expression and reduced the yield of infectious HCMV below the detection limit (FIG. 3). These results demonstrate that compounds activating SIRT1 block the production of infectious HCMV, and, therefore, have utility as antiviral drugs in the treatment of HCMV infections.
  • Next, to further confirm the anti-viral effect of sirtuins observed in siRNA experiments, small molecule inhibitors which block the activity of one or multiple sirtuins, were evaluated for effects on HCMV replication. As used herein, the term “sirtuin antagonist” or “sirtuin inhibitor” refers to a compound that decreases sirtuin activity. The compound can be a small molecule, nucleic acid, protein, or peptide. In some embodiments, the sirtuin antagonist is a dual antagonist, referring to its ability to decrease activity of two sirtuins. More specifically, disclosed herein are SIRT1/SIRT2 dual inhibitors, including, but not limited to cambinol, tenovin 6, tenovin 1, salermide, sirtinol, and combinations thereof. Further disclosed herein are combinations of a SIRT1 inhibitor and a SIRT2 inhibitor.
  • Several sirtuin inhibitors have been reported in literature. Among these, EX-527, is a highly selective to SIRT1 (Solomon et al., 2006, Mol Cell Biol 26, 28-38) having a structure
  • Figure US20130338178A1-20131219-C00009
  • Another SIRT1 inhibitor is (S)-35 which has a structure
  • Figure US20130338178A1-20131219-C00010
  • Cambinol inhibits NAD dependent deacetylase activity of both SIRT1 and SIRT2 (Heltweg et al., 2006, Cancer Res 66, 4368-77). Supporting the phenotype of the siRNA-mediated SIRT1 knockdown, 10 μM EX-527 increased the accumulation of late viral pUL99 protein (data not shown) and production of infectious HCMV progeny by a factor of −4 fold in MRC5 fibroblasts (FIG. 4).
  • The dual SIRT1/SIRT2 inhibitor Cambinol, having a structure of
  • Figure US20130338178A1-20131219-C00011
  • showed a substantial block of pUL99 accumulation (data not shown) at 50 μM and the yield of infectious HCMV was below detection limit (<102 IU/ml) at this concentration of drug (FIG. 4). Cambinol is well-tolerated in mice and inhibits Burkitt lymphoma xenografts. The dual SIRT1/SIRT2 inhibitors Tenovin-6 and Salermide also blocked the production of infectious HCMV (FIG. 5). By blocking SIRT1 and 2, cambinol, tenovin-6 and salermide induce hyperacetylation of the p53 tumor suppressor protein, which is required for its activation during stress. p53 plays a major role in cell-cycle control, it contributes to virus-induced apoptosis, and it is a direct activator of type I interferons that induce antiviral defense. Several viruses require inactivation of p53 for efficient replication. Therefore these results demonstrate that multiple SIRT1/SIRT2 inhibitors have antiviral activity, and strongly predict that dual SIRT1 and SIRT2 inhibitors constitute a class of novel antiviral agents that inhibit HCMV as well as other viruses that require inactivation of p53. A list of non-limiting exemplary inhibitors is presented in Table 2. Tenovin 1 has a structure of
  • Figure US20130338178A1-20131219-C00012
  • Tenovin 6 has a structure of
  • Figure US20130338178A1-20131219-C00013
  • Salermide has a structure of
  • Figure US20130338178A1-20131219-C00014
  • Sirtinol has a structure of
  • Figure US20130338178A1-20131219-C00015
  • TABLE 2
    Compound Target IC50
    Tenovin 1 SIRT 1 and 2 21, 10, and 67 μM
    respectively
    Tenovin 6 SIRT1, 2 and 3 21, 10, and 67 μM,
    respectively
    Salermide SIRT1 and 2 76.2 and 45 μM
    respectively
    Sirtinol SIRT1 and 2 131 and 57.7 respectively
    Cambinol SIRT1 and 2 56 and 59 μM respectively
  • Dual SIRT1/SIRT2 inhibitors are thought to act in part by blocking the ability of sirtuins to inhibit and consequently activating the tumor suppressor protein p53 (see Heltweg et al., 2006 and references therein). Therefore the possibility that p53 activity is needed for dual SIRT1/SIRT2 inhibitors to inhibit the production of HCMV progeny was tested (FIG. 6). Results showed that salermide inhibited the production of HCMV progeny by a factor of nearly 80 in cells expressing p53. In contrast, the drug inhibited HCMV production by a factor of only about 5 in cells in which p53 levels were substantially reduced by knockdown with a p53-specific shRNA. This observation reveals that dual SIRT1/SIRT2 inhibitors inhibit HCMV production at least in part through a p53-dependent mechanism. Many viruses are known to block the activity of p53 as part of their strategy for successful replication. The block can be achieved by degradation of a substantial portion of the cellular p53, by interaction with a viral protein that inhibits p53 activity or by posttranslational modification of p53, including changes in acetylation status. Dual SIRT1/SIRT2 inhibitors can relieve the block either by hyper-activation of residual active p53 or re-activation of inactivated p53. Therefore, the demonstration of a role for p53 predicts that any virus that inactivates p53 will be sensitive to dual SIRT1/SIRT2 inhibitors. Contemplated viruses that inactivate p53 include, but are not limited to, Adenoviridae (Adenovirus, with E1B-55K as a p53 inactivating protein); Hepadnaviridae (HBV, with X protein a p53 inactivating protein); Herpesviridae (EBV, with LMP1 a p53 inactivating protein; HSV-1 with ICP0 as a p53 inactivating protein; HCMV, with IE1 as a p53 inactivating protein; KSHV with LANA as a p53 inactivating protein); Flaviviridae (HCV with NS5A as a p53 inactivating protein); Orthomixoviridae (Influenza A with NS1 as a p53 inactivating protein); Papillomaviridae (HPV with E6 as a p53 inactivating protein); Polyomaviridae (SV40 with Large T-antigen as a p53 inactivating protein; JC virus with Large T-antigen as a p53 inactivating protein; BK virus with Large T antigen as a p53 inactivating protein); and Retroviridae (HIV with Tat as a p53 inactivating protein).
  • In addition to dual SIRT1/SIRT 2 inhibitors (or inhibitors of two or more sirtuins), further contemplated are combination administration of two sirtuin inhibitors, e.g., a SIRT1 inhibitor and a SIRT2 inhibitor or a SIRT1 inhibitor and SIRT3 inhibitor, or a SIRT2 inhibitor and a SIRT3 inhibitor, or other combinations of sirtuin inhibitors as disclosed above, to achieve dual inhibition of the sirtuins.
  • SIRT1 inhibitors include EX-527 and (S)-35 as noted above, and HR73, having a structure
  • Figure US20130338178A1-20131219-C00016
  • SIRT2 inhibitors include Ro31-8220 having a structure
  • Figure US20130338178A1-20131219-C00017
  • Other sirtuin inhibitors contemplated include the following but specifically exclude suramin (see, e.g., Trapp, et al., Chem. Med. Chem., 2:1419-1431 (2007)):
  • Figure US20130338178A1-20131219-C00018
    compound R
    5a suramin
    Figure US20130338178A1-20131219-C00019
    5b NF037
    Figure US20130338178A1-20131219-C00020
    5c NF127
    Figure US20130338178A1-20131219-C00021
    5d NF151
    Figure US20130338178A1-20131219-C00022
    5e NF157
    Figure US20130338178A1-20131219-C00023
    5f NF198
    Figure US20130338178A1-20131219-C00024
    5g NF222
    Figure US20130338178A1-20131219-C00025
    5h NF258
    Figure US20130338178A1-20131219-C00026
    5i NF260
    Figure US20130338178A1-20131219-C00027
  • Figure US20130338178A1-20131219-C00028
    compound R1 R2 R3
    6a NF342
    Figure US20130338178A1-20131219-C00029
    Figure US20130338178A1-20131219-C00030
    Figure US20130338178A1-20131219-C00031
    6b NF674
    Figure US20130338178A1-20131219-C00032
    Figure US20130338178A1-20131219-C00033
    Figure US20130338178A1-20131219-C00034
    6c NF675
    Figure US20130338178A1-20131219-C00035
    Figure US20130338178A1-20131219-C00036
    Figure US20130338178A1-20131219-C00037
  • Figure US20130338178A1-20131219-C00038
    compound R
    7a NF023
    Figure US20130338178A1-20131219-C00039
    7b NF150
    Figure US20130338178A1-20131219-C00040
    7c NF156
    Figure US20130338178A1-20131219-C00041
    7d NF259
    Figure US20130338178A1-20131219-C00042
    7e NF058
    Figure US20130338178A1-20131219-C00043
  • Figure US20130338178A1-20131219-C00044
    compound R
    8a NF763
    Figure US20130338178A1-20131219-C00045
    8b NF770
    Figure US20130338178A1-20131219-C00046
  • Figure US20130338178A1-20131219-C00047
    compound R
    9a NF290
    Figure US20130338178A1-20131219-C00048
    9b NF762
    Figure US20130338178A1-20131219-C00049
    9c NF769
    Figure US20130338178A1-20131219-C00050
  • compound
    10 NF136
    Figure US20130338178A1-20131219-C00051
    11 NF444
    Figure US20130338178A1-20131219-C00052
    12 NF343
    Figure US20130338178A1-20131219-C00053
      13a    13b NF443 n = 1 NF451 n = 0
    Figure US20130338178A1-20131219-C00054
      14a  14b NF154 NF155
    Figure US20130338178A1-20131219-C00055
    15 NH669
    Figure US20130338178A1-20131219-C00056
    16 AMI1
    Figure US20130338178A1-20131219-C00057
  • Further contemplated sirtuin inhibitors include the following (see, e.g., Medda, et al., J. Med. Chem., 52:2673-2682 (2009)):
  • Figure US20130338178A1-20131219-C00058
    • 1 R1═R2═H, X═S, Cambinol 6a R1═R2═H, X═O
  • 6b R1=p-Br, R2═H, X═S
    6c R1=p-OMe, R2═H, X═S
    • 6e R1═H, R2=Me, X═S
  • 6i-xi R2—H, X—S
    6f,g,j R1═H, X═S, R2 varies
  • TABLE 1
    Inhibition (at 60 μM ± SEa (%)) of Sirtuins by the Novel
    Analogs 6i-xi and 6a-6j
    Compd R1 R2 X SIRT1 IC50 b SIRT2 IC50 b
    1 H H S 59.5 ± 1 40.7 ± 11 51.9 ± 1 47.9 ± 12
    6a H H O 15.5 ± 2  6.5 ± 4
    6b p-Br H S 82.3 ± 1 12.7 ± 2  9.4 ± 1 >90
    6c p-CH3O H S  6.4 ± 1  9.2 ± 2
    6d H H S 37.8 ± 1 52.7 ± 2
    6i o-CH3 H S 79.6 ± 1 43.0 ± 2 29.1 ± 2
    6ii m-CH3 H S 83.2 ± 4 44.2 ± 2 12.7 ± 2
    6iii p-CH3 H S 79.0 ± 2 44.5 ± 1 13.4 ± 3
    6iv p-Cl H S 13.7 ± 1 20.1 ± 1
    6v p-I H S  7.7 ± 1  7.7 ± 1
    6vi p-CF3 H S 15.1 ± 1  6.7 ± 1
    6vii o-Br H S 19.7 ± 1
    6viii m-Br H S  4.8 ± 1  6.6 ± 3
    6ix m-Cl H S 11.3 ± 1  7.6 ± 6
    6x o-F H S 89.0 ± 1 50.0 ±1 19.5 ± 1
    6xi m-F H S 87.8 ± 1 38.3 ± 1 52.1 ± 1
    6e H Me S 29.4 ± 1 >90 80.4 ± 1 20.1 ± 5
    6f H Et S 31.9 ± 1 86.8 ± 1 10.5 ± 3
    6g H allyl S 37.5 ± 1 88.3 ± 1 22.2 ± 1
    6h H n-prop S 25.0 ± 2 94.7 ± 1  4.8 ± 2
    6j H n-But S 16.9 ± 1 97.6 ± 1  1.0 ± 1
    aSE, standard error (n = 2).
    bIC50 values were determined for compounds that had over 60% inhibition at 60 μM for SIRT1 and SIRT2 (repeated at least twice).
  • Also contemplated as SIRT1 and SIRT2 inhibitors are the following (see, e.g., Napper, et al., J. Med. Chem., 48:8045-8054 (2005)):
  • Figure US20130338178A1-20131219-C00059
    IC50
    compd R1 R2 R3 R4 R5 (μM)a
     1 Cl H H CONH2 H 0.098
     1(e1) Cl H H CONH2 H 0.123
     1(e2) Cl H H CONH2 H >100
     2 CH H H CONH2 H 0.205
     3 H H H CONH2 H 1.47
     5 Cl H H CO2Et H >100
     8 Cl H H CO2H H >100
    12 OH H H CONH2 H 15.0
    15 Cl H H CONHOH H 77.6
    26 Cl H H H CONH2 34.5
    27 Br H H H CONH2 2.44
    36 Cl H H CONHEt H >100
    37 Cl H H CONEt2 H >100
    38 Cl H H CONHCH2CONH2 H >100
    39 CH3 H H CH2NH2 H >100
    40 CH3 CH3 H CONH2 H >100
    41 CH3 H CH3 CONH2 H 13.0
    aData are reported as the mean of at least three independent determinations; standard error of the mean ≦30%.
  • Figure US20130338178A1-20131219-C00060
    Figure US20130338178A1-20131219-C00061
         		13
    IC50
    compd R n X (μM)a
     1 Cl 1 CH2 0.098
     3 H 1 CH2 1.47
    13 — — — >100
    20 Cl 1 NH 18.0
    21 Br 1 NH >100
    23 Cl 1 NHCOCH3 79.9
    30 Cl 0 CH2 0.409
    31 H 0 CH2 2.67
    35 Cl 2 CH2 0.124
    (S)-35 Cl 2 CH2 0.063
    (R)-35 Cl 2 CH2 23.0
    aData are reported as the mean of at least three independent determinations; standard error of the mean ≦30%.
  • Further contemplated are sirtuin inhibitors having the following structures (see e.g. Bodner, et al., PNAS, 103(11):4246-4251 (2006) and Outeiro et al., Science, 317:516-519 (2007)):
  • Figure US20130338178A1-20131219-C00062
  • Also contemplated are sirtuin inhibitors having the following structures (see, e.g., Kiviranta, et al., J Med. Chem., 49(26):7907 (2006)):
  •
    Figure US20130338178A1-20131219-C00063
         		BML-266
    Figure US20130338178A1-20131219-C00064
         		2
    Figure US20130338178A1-20131219-C00065
         		3
    inhibition at
    compd R1 R2 R3 200 μM ± SD,a %
    3a H H H 35 ± 1.4
    3b OH H H 56 ± 8.2
    3c H OH H 12 ± 0.9
    3d H H OH 22 ± 1.6
    3e H OH OH 13 ± 0.2
    3f OCH3 H H 13 ± 0.5
    3g H OCH3 H 20 ± 1.2
    3h H H OCH3 NDb
    aSD = standard deviation.
    bThe product did not dissolve.
  • 4
    Figure US20130338178A1-20131219-C00066
    inhibition at
    compd R1 R2 R3 200 μM ± SD.a %
    4a H H H 21 ± 1.7
    4b OH H H 27 ± 2.4
    4c H OH H  8 ± 0.4
    4d H H OH 14 ± 0.5
    aSD = standard deviation.
  • 5
    Figure US20130338178A1-20131219-C00067
    inhibition at
    compd R1 R2 R3 200 mM ± SD,a %
    5a H H H 18 ± 0.5
    5b OH H H 38 ± 1.2
    5c H OH H 53 ± 1.9
    5d H H OH 64 ± 1.9
    5e OCH3 H H 34 ± 1.2
    5f H OCH3 H 20 ± 0.2
    5g H H OCH3 17 ± 1.1
    aSD = standard deviation.
  • Further contemplated are sirtuin inhibitors as shown below (see, e.g., Sanders, et al., Bioorg. Med. Chem., 17(19):7031-7041 (2009)).
  •
    Figure US20130338178A1-20131219-C00068
         		surfactin (7)
    Figure US20130338178A1-20131219-C00069
         		(10)
    Figure US20130338178A1-20131219-C00070
         		(11)
    Figure US20130338178A1-20131219-C00071
         		(12)
    Figure US20130338178A1-20131219-C00072
         		(13)
    Figure US20130338178A1-20131219-C00073
         		(14a)
    Figure US20130338178A1-20131219-C00074
         		(14b)
    Compound Hst2 IC50 (μM) SIRT1 IC50 (μM)
    Nicotinamide (1) 91 ± 7  250 ± 80 
    Sirtinol (2) 48 ± 11 120 ± 23 
    Splitomycin (3) >600 >500
    Cambinol (4) >1000  >600
    Tenovin-6 (5)  >100*  ~100*
    Ro 31-8220 (6) 20.0 ± 0.9  25 ± 7 
    Surfactin (7) >700 >600
    Suramin (8) 240 ± 70  0.6 ± 0.3
    Indole 35 (9) 1.3 ± 0.1 0.18 ± 0.02
    Indole 2 (10) 14.5 ± 0.6  0.64 ± 0.06
    11 6.5 ± 1.3 6.0 ± 0.4
    12 19.9 ± 0.6  80 ± 5 
    13 12.5 ± 0.6  34 ± 10
    14a 130 ± 4  570 ± 200
    14b 260 ± 20  nd
  • Figure US20130338178A1-20131219-C00075
    % Activity % Activity
    Compound R1 R2 R3 at 50 μM at 500 μM
    7-133 H H
    Figure US20130338178A1-20131219-C00076
         		100 98
    7-52 
    Figure US20130338178A1-20131219-C00077
         		H
    Figure US20130338178A1-20131219-C00078
         		100 86
    7-56 
    Figure US20130338178A1-20131219-C00079
         		H
    Figure US20130338178A1-20131219-C00080
         		96 70
    7-57 
    Figure US20130338178A1-20131219-C00081
         		H
    Figure US20130338178A1-20131219-C00082
         		97 74
    14a
    Figure US20130338178A1-20131219-C00083
         		H
    Figure US20130338178A1-20131219-C00084
         		76 5
    14b
    Figure US20130338178A1-20131219-C00085
         		H
    Figure US20130338178A1-20131219-C00086
         		92 2
    7-128
    Figure US20130338178A1-20131219-C00087
         		H
    Figure US20130338178A1-20131219-C00088
         		99 92
    7-129
    Figure US20130338178A1-20131219-C00089
         		H
    Figure US20130338178A1-20131219-C00090
         		97 94
    7-123
    Figure US20130338178A1-20131219-C00091
    Figure US20130338178A1-20131219-C00092
    Figure US20130338178A1-20131219-C00093
         		100 100
    Data are reported as the percent of residual enzyme activity in the presence of 50 or 500 μM compound relative to the control reaction with no added inhibitor.
    Data are reported as the average of three independent determinations, standard deviation of the average ≦ 10%.
  • Figure US20130338178A1-20131219-C00094
    Compound A B R1 R2 R3 R4 R5 R6 % Activity at 50 μM % Activity at 500 μM
    11 CH2 CH2 H H CH2CH3
    Figure US20130338178A1-20131219-C00095
         		— — <1 <1
    5140108 — — H CH3 H — CH3 H 90 13
    6959933 CH2 CH2 H H OCH3 — CH3 H 93 35
    5237467 — — H H H — CH3 H 91 45
    7985301 CH2 CH2 CH3 H CH3
    Figure US20130338178A1-20131219-C00096
         		— — 93 49
    7988362 CH2 CH2 CH3 H CH3 — CH3 H 90 51
    6802623 CH2 CH2 H H CH2CH3 — CH3 H 86 53
    6836332 CH2 CH2 H H CH3 — CH3 H 99 57
    6978945 CH2 CH2 H H OCH3
    Figure US20130338178A1-20131219-C00097
         		— — 95 58
    5366302 CH2 CH2 Cl H Cl — CH3 H 90 68
    53378 CONH CH2 H H H — CH3 Cl 100 74
    Data are reported as the percent of residual enzyme activity in the presence of 50 or 500 μM compound relative to the control reaction with no added inhibitor.
    Data are reported as the average of three independent determinations, standard deviation of the average ≦10%.
  • Figure US20130338178A1-20131219-C00098
    Compound R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 % Activity at 50 μM % Activity at 500 μM
    13 Cl Cl H Cl OH Cl Cl H Cl OH H <1 <1
    97252 H CH3 OH CH3 H H CH3 OH CH3 H H 89 43
    97211 H H CF3 H H H H H H H OH 100 81
    72030 H H H H H H H OH H H H 100 88
    56413 H H H NH2 H H NH2 H H H H 100 100
    43909 Cl H H H H OH
    Figure US20130338178A1-20131219-C00099
         		H H NHCOCH 3 100 100
    Data are reported as the percent of residual enzyme activity in the presence of 50 or 500 μM compound relative to the control reaction with no added inhibitor.
    Data are reported as the average of three independent determinations, standard deviation of the average ≦10%.
  • Figure US20130338178A1-20131219-C00100
    Compound R1 R2 R3 R4 IC50 (μM)
    12
    Figure US20130338178A1-20131219-C00101
         		H H H 19.9 ± 0.5
    39008
    Figure US20130338178A1-20131219-C00102
    Figure US20130338178A1-20131219-C00103
         		Cl Cl No inhibition
    47054
    Figure US20130338178A1-20131219-C00104
    Figure US20130338178A1-20131219-C00105
    Figure US20130338178A1-20131219-C00106
         		H No inhibition
    42071
    Figure US20130338178A1-20131219-C00107
         		H NH2 H No inhibition
    47032
    Figure US20130338178A1-20131219-C00108
    Figure US20130338178A1-20131219-C00109
         		H H No inhibition
    04265
    Figure US20130338178A1-20131219-C00110
    Figure US20130338178A1-20131219-C00111
         		H H No inhibition
    91032
    Figure US20130338178A1-20131219-C00112
    Figure US20130338178A1-20131219-C00113
         		H H No inhibition
    00032
    Figure US20130338178A1-20131219-C00114
    Figure US20130338178A1-20131219-C00115
         		H H No inhibition
  • Further contemplated are sirtuin inhibitors disclosed below (see, e.g., Schlicker, et al., Aging, 3(9):852 (2011)):
  • Figure US20130338178A1-20131219-C00116
    Figure US20130338178A1-20131219-C00117
  • cmp- NCS
    no. no. Chemical structure
    CSC1  11241
    Figure US20130338178A1-20131219-C00118
    CSC2  12339
    Figure US20130338178A1-20131219-C00119
    CSC3  12363
    Figure US20130338178A1-20131219-C00120
    CSC4  13726
    Figure US20130338178A1-20131219-C00121
    CSC5  13728
    Figure US20130338178A1-20131219-C00122
    CSC6  23128
    Figure US20130338178A1-20131219-C00123
    CSC7  23217
    Figure US20130338178A1-20131219-C00124
    CSC8  26645
    Figure US20130338178A1-20131219-C00125
    CSC9  35049
    Figure US20130338178A1-20131219-C00126
    CSC11 35949
    Figure US20130338178A1-20131219-C00127
    CSC12 37245
    Figure US20130338178A1-20131219-C00128
    CSC13 39863
    Figure US20130338178A1-20131219-C00129
    CSC14 51535
    Figure US20130338178A1-20131219-C00130
    CSC15 63875
    Figure US20130338178A1-20131219-C00131
    CSC16 72254
    Figure US20130338178A1-20131219-C00132
    CSC17 74702
    Figure US20130338178A1-20131219-C00133
    CSC18 79050
    Figure US20130338178A1-20131219-C00134
    CSC19 90318
    Figure US20130338178A1-20131219-C00135
    CSC20 94820
    Figure US20130338178A1-20131219-C00136
    CSC21 95090
    Figure US20130338178A1-20131219-C00137
    CSC22 99515
    Figure US20130338178A1-20131219-C00138
    CSC23 99543
    Figure US20130338178A1-20131219-C00139
    CSC24 99550
    Figure US20130338178A1-20131219-C00140
    CSC25 105550
    Figure US20130338178A1-20131219-C00141
    CSC26 111326
    Figure US20130338178A1-20131219-C00142
    CSC27 115448
    Figure US20130338178A1-20131219-C00143
    CSC28 119886
    Figure US20130338178A1-20131219-C00144
    CSC29 122140
    Figure US20130338178A1-20131219-C00145
    CSC30 125252
    Figure US20130338178A1-20131219-C00146
    CSC31 128609
    Figure US20130338178A1-20131219-C00147
    CSC32 132230
    Figure US20130338178A1-20131219-C00148
    CSC33 135371
    Figure US20130338178A1-20131219-C00149
    CSC34 234766
    Figure US20130338178A1-20131219-C00150
    CSC35 282058
    Figure US20130338178A1-20131219-C00151
    CSC36 299137
    Figure US20130338178A1-20131219-C00152
    CSC37 300545
    Figure US20130338178A1-20131219-C00153
    CSC38 309883
    Figure US20130338178A1-20131219-C00154
    CSC39 351123
    Figure US20130338178A1-20131219-C00155
    CSC40 402959
    Figure US20130338178A1-20131219-C00156
    Figure US20130338178A1-20131219-C00157
  • Compound (NCS) Sirt2 Sirt3 Sirt5 Sirt6
    CSC1 (11241) inhibitiona inhibition inhibition inhibition
    CSC2 (12339) inhibition — — —
    CSC3 (12363) — — — —
    CSC4 (13726) inhibition — — —
    CSC5 (13728) n.c.b n.c. n.c. n.c.
    CSC6 (23128) inhibition — — inhibition
    CSC7 (23217) inhibition — — —
    CSC8 (26645) inhibition — — —
    CSC9 (35049) inhibition — activationc —
    CSC10 (35489) inhibition inhibition — inhibition
    CSC11 (35949) — — — —
    CSC12 (37245) — — — —
    CSC13 (39863) inhibition — — —
    CSC14 (51535) inhibition — inhibition —
    CSC15 (63875) — — — —
    CSC16 (72254) — — — —
    CSC17 (74702) — — — —
    CSC18 (79050) — — — —
    CSC19 (90318) — — — —
    CSC20 (94820) — — — —
    CSC21 (95090) inhibition — inhibition inhibition
    CSC22 (99515) inhibition — — —
    CSC23 (99543) inhibition — — —
    CSC24 (99550) inhibition — — —
    CSC25 (105550) — — — —
    CSC26 (111326) — — — —
    CSC27 (115448) inhibition — — inhibition
    CSC28 (119886) inhibition — — activation
    CSC29 (122140) — — — —
    CSC30 (125252) — — — —
    CSC31 (128609) — — — —
    CSC32 (132230) inhibition — — —
    CSC33 (135371) — — activation activation
    CSC34 (234766) inhibition — — activation
    CSC35 (282058) — — — —
    CSC36 (299137) — — — —
    CSC37 (300545) inhibition — — —
    CSC38 (309883) inhibition — activation activation
    CSC39 (351123) — — — —
    CSC40 (402959) n.c. n.c. n.c. n.c.
  • Further contemplated are sirtuin inhibitors disclosed below (see, e.g., Yasuda, et al., Analytical Chem., 83:7400-7407 (2011)): quercetin and vitexin, as SIRT6 inhibitors.
  • Further contemplated are sirtuin inhibitors disclosed below (see, e.g., Kalle, et al. Biochem. Biophys. Res. Comm., 401:13-19 (2010):
  • Figure US20130338178A1-20131219-C00158
  • Further contemplated are sirtuin inhibitors disclosed below (see, e.g., Asaba, et al., J. Am. Chem. Soc., 131:6989-6996 (2009)):
  • Figure US20130338178A1-20131219-C00159
    compound R inhibition at 300 μM (%) IC50 (μM)
    2a —CN  50 ± 7.9 300 ± 6.2
    2b —CF3 44 ± 17 >300
    2c —SCH3 32 ± 20 >300
    2d —SOCH3  46 ± 3.0 >300
    2e —SO2CH3  56 ± 1.9 N.D.d
    2f 2-CF3Ph 49 ± 13 >300
    2g 4-CF3Ph 41 ± 20 >300
    2h 2-NO2Ph 40 ± 12 >300
    2i 4-NO2Ph 51 ± 17 N.D.d
    2j —COOCH3  92 ± 1.2  35 ± 5.2
    2k —COOEt  91 ± 1.3  3.9 ± 0.29
    2l —COOn-Pr   71 ± 0.72  62 ± 3.7
    2m —COOi-Pr  72 ± 5.1  47 ± 5.3
    2n —COOn-Bu  64 ± 6.1  73 ± 3.2
    2o —COOt-Bu  6.0 ± 0.64 >300
    2p —COOCH2-c-Pr  93 ± 1.2  14 ± 2.6
    2q —COOCH2CF3  94 ± 1.5  15 ± 3.1
    2r —COOCH2Ph  71 ± 4.3  96 ± 4.8
    2s —CONH2  25 ± 2.3 >300
    2t —CONHCH3  24 ± 2.5 >300
    2u —CON(CH3)2  20 ± 1.3 >300
    2v —COCH3  45 ± 6.0 >300
    2w —COEt  67 ± 1.2  88 ± 3.9
    2x —COn-Pr  78 ± 5.2  56 ± 5.3
    2y —COCF3  7.9 ± 0.92 >300
    2z —COPh  37 ± 7.4 >300
    a SIRT1 was preincubated with NAD+ and compounds 2a-z, and then acetylated lysine substrate was added.
    b Values are means ± SD determined from at least three experiments.
    c Nicotinamide22 (IC50 = 25 ± 5.1 μM) and EX-52712 (IC50 = 1.4 ± 0.23 μM) were used as positive controls.
    dN.D. = not determined.,

    and in particular 2k.
  • Further contemplated are sirtuin inhibitors as disclosed below (see, e.g., Gutierrez, et al., J. Org. Chem., 74:5267-5275 (2009)):
  • Figure US20130338178A1-20131219-C00160
  • and in particular compounds 4, 5, and ent-5 as SIRT2 inhibitors.
  • Further contemplated are sirtuin inhibitors as disclosed below (see, e.g., Zhang, et al., Biochem. Biophys. Res. Comm., 386:729-733 (2009)):
  • Figure US20130338178A1-20131219-C00161
    • (AC-93253).
  • Further contemplated are sirtuin inhibitors as disclosed below (see, e.g., Huber, e t al., J. Med. Chem., 53:1383-1386 (2010)):
  • Figure US20130338178A1-20131219-C00162
  • TABLE 1
    Sirtuin Inhibition
    IC50 ± SE [μM] or
    Com- inhibition [%] @ 50 μM
    pound Ar SIRT1 SIRT2 SIRT3
    2 — 41.6 ± 0.7 15.6 ± 1   25.1 ± 0.6
    3 — NAa 87.2 ± 9.5 NA
    Suni- — NA 122.7 ± 23.6 26.4%
    tinib
    4
    Figure US20130338178A1-20131219-C00163
         		40.6 ± 6.6 28.4 ± 2.5 23.6 ± 0.4
    5
    Figure US20130338178A1-20131219-C00164
         		NA 34.7% 13.5%
    6
    Figure US20130338178A1-20131219-C00165
         		NA NA NA
    7
    Figure US20130338178A1-20131219-C00166
         		24.4% 33.4 ± 5.6 NA
    8
    Figure US20130338178A1-20131219-C00167
         		20.7% NA NA
    9
    Figure US20130338178A1-20131219-C00168
         		30.2% 10.4 ± 1.4 NA
    10 
    Figure US20130338178A1-20131219-C00169
         		19.9% 135.4 ± 14.8 NA
    11 
    Figure US20130338178A1-20131219-C00170
         		22.7% 20.6% NA
    12 
    Figure US20130338178A1-20131219-C00171
         		19.6% 16.5% NA
    13 
    Figure US20130338178A1-20131219-C00172
         		45.4% 18.3% NA
    14 
    Figure US20130338178A1-20131219-C00173
         		19.8% 10.1% NA
    aInhibition of <10% at 50 μM.
  • Other inhibitors of sirtuin(s) include the cyclic lipopeptide surfactin or derivatives thereof (see, Chakrabarty et al., Molec. Biochem. Parasitol., 158:139-151 (2008).
  • Other inhibitors of sirtuin(s) include microRNA, such as disclosed in, e.g., Gambari, et al., Biochem. Pharmacol., 82:1416-1429 (2011), Yamakuchi et al., PNAS, 105(36):13421-13426 (2008), Xu, et al., J. Cell. Biol., 193:409-124 (2011), or more specifically miR-34a, miR-22, or a derivative thereof as a sirtuin inhibitor.
  • B2, AGK2, and BML-266 are each SIRT2 inhibitors. EX-527 and (S)-35 are each SIRT1 inhibitors. Specifically contemplated are administration of a SIRT2 inhibitor selected from B2, AGK2, BML-266, or combinations thereof and a SIRT1 inhibitor selected from EX-527, (S)-35, and combinations thereof.
  • Since p53 is at least partially responsible for the ability of dual SIRT1/SIRT2 inhibitors to block HCMV replication (FIG. 6) and other sirtuins have been shown to alter the activity of p53 (see, e.g., Li et al., PLoS One 5, e10486, 2010), it is further contemplated that drugs inhibiting combinations of sirtuins in addition to SIRT1/SIRT2 dual inhibitors inhibit HCMV replication and the replication of other viruses that depend on the inactivation of p53. Specifically contemplated are administration of drugs that inhibit two or more sirtuins, including SIRT1 plus SIRT2, SIRT1 plus SIRT2 plus another sirtuin, SIRT1 plus one or more sirtuins that do not include SIRT2, SIRT2 plus one or more sirtuins that do not include SIRT1, or a combination of two or more sirtuins that do not include SIRT1 or SIRT2. As such, these combinations of sirtuin inhibitors are disclosed herein as antiviral therapeutics. Thus the present disclosure includes methods of treating a viral infection by administering one or more inhibitors of two or more sirtuins. Further contemplated are methods of administering inhibitors of multiple sirtuins and further administering one or more activators of one or more of the sirtuins that are not inhibited, or combinations of drugs that inhibit and activate different sirtuins. For example, contemplated are methods of treating a viral infection comprising administering a SIRT1 inhibitor, a SIRT2 inhibitor, and a SIRT3 activator (agonist) to subject in need thereof.
  • The present disclosure includes methods of treating HCMV infections using activators of any, a subset or all of seven sirtuins. Also provided is the use of therapeutics that simultaneously inhibit SIRT1 and SIRT2 (or, more generally, simultaneously inhibiting two or more sirtuins) to treat HCMV infections. These inhibitors include without limitation small molecules, nucleic acids, proteins, and peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • In addition to HCMV, siRNA screens were performed to test whether sirtuins also inhibit the replication of herpes simplex type 1 (HSV1), adenovirus (Ad5) and influenza A (Flu A) viruses. Each of these viruses generated elevated yields in response to knock down of multiple, individual siRNAs (FIG. 7). This result leads to a conclusion that sirtuin activators will inhibit not only HCMV, but also herpes simplex viruses, adenoviruses and influenza viruses. Given the diversity of these viruses (both slow and fast growing; both RNA and DNA viruses), the results predict that sirtuin agonists will exhibit broad spectrum antiviral activity. Thus, the present disclosure includes the use of sirtuin agonists as broad spectrum antiviral therapeutics.
  • In addition to HCMV, the dual SIRT1/SIRT2 inhibitors cambinol and saleramide inhibited the production of infectious progeny for two Influenza A viruses, WSN/33 and PR8, in two different cell types, MRC5 fibroblasts and MDCK epithelial cells. The dual inhibitors reduced virus replication to a greater extent than did oseltamivir (TamiFlu®) which was included as a comparator (FIG. 8), and cambinol cooperated with oseltamivir to inhibit influenza A (FIG. 9). The dual inhibitors also blocked the production of adenovirus progeny (FIG. 10). Thus, dual SIRT1/SIRT2 inhibitors inhibit not only HCMV, but also influenza A and adenoviruses, making dual SIRT1/SIRT2 inhibitors broad spectrum antivirals that are useful for treatment as a single agent or in combination with other agents, as described further below.
  • Embodiments herein include methods of treating viral infections, including HCMV and adenovirus infections, using dual SIRT1 and 2 inhibitors (or more generally, inhibitors of two or more sirtuins), and optionally in combination with activators of another sirtuin. These sirtuin modulators include without limitation small molecules, nucleic acids, proteins, and derivatives thereof. Additional small molecule activators and inhibitors can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Sirtuin agonists, dual SIRT1 and SIRT2 inhibitors, and inhibitors of two or more sirtuins have utility as anti-viral drugs.
  • The work herein is the first to show that the yields of HCMV are induced by inhibition of individual sirtuins and therefore indicate that induction of sirtuin levels or activity or both would inhibit the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny. Modulation of each of the seven sirtuins can influence viral replication and therefore predict that induction of any one of the different known sirtuin activities will inhibit the production of HCMV progeny. These results also raise the possibility that induction of multiple sirtuins will synergistically inhibit the production of HCMV progeny. Importantly, simultaneous inhibition of SIRT1 and SIRT2 inhibits HCMV, in spite of the fact that inhibition of either separately increases virus yield.
  • Embodiments include inhibition of HCMV by agonists of one or more sirtuin (SIRT1-7), and the agonists. Some agonists may only target one sirtuin, but one or more agonists targeting multiple sirutins may also be provided. An embodiment includes an agonist of one or more of the mitochondrial sirtuins (SIRT3-5), because the siRNA data reveals that modulation of SIRT3 and SIRT5 has the greatest effect on HCMV yield.
  • Embodiments include inhibition of a virus by antagonists of SIRT1 and SIRT2, or antagonists of two or more sirtuins (SIRT1-7), and the agents capable of causing the inhibition. The virus may be HCMV. The virus may be one that must inactivate p53 in order to produce an optimal yield of infectious progeny or maintain itself within an infected cell. The virus may be any virus. Inhibition can be accomplished using drugs that inhibit both sirtuins or by using a combination of two drugs, one of which inhibits SIRT1 and the other of which inhibits SIRT2.
  • Embodiments include methods of treating viral infections. Embodiments include methods of treating HCMV infections in human patients. The methods include a step of administering agonists, or activators, of any sirtuin, agonists of a subset sirtuins or agonists all of seven sirtuins to a patient. These agonists include without limitation at least one of small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Embodiments include methods of treating viral infections. Embodiments include methods of treating HCMV infections in mammals, or more specifically human patients. Embodiments include methods of treating viral infections where the virus requires p53 inactivation. The methods include a step of administering antagonists of sirtuins, in particular antagonists of both SIRT1 and SIRT2 to a patient. These antagonists include without limitation at least one of small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule antagonists can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Embodiments include anti-viral drugs that may be used for treating viral infections. The anti-viral drugs may be agonists or antagonists of any sirtuin, agonists or antagonists of a subset sirtuins or agonists or antagonists all of seven sirtuins. These activators include without limitation small molecules, nucleic acids, proteins, or peptide based activators. Beyond those described herein, additional small molecule activators can be found by screening of compound libraries and/or design of molecules that bind to specific pockets in the structures of these enzymes. The properties of these molecules can be optimized through derivatization, including iterative rounds of synthesis and experimental testing.
  • Further disclosed herein are methods that further comprise contacting a virus with a second agent, e.g., an anti-viral agent that is not the SIRT1 and SIRT2 inhibitors or the sirtuin agonist or a second agent that is a different SIRT1 and/or SIRT2 inhibitor or sirtuin agonist as disclosed herein. Contemplated second agents include, without limitation, acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, immunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor, lamivudine, lopinavir, loviride, mk-0518, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleotide and/or nucleoside analogues, oseltamivir, penciclovir, peramivir, podophyllotoxin, rimantadine, ritonavir, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, morpholino oligonucleotides, ribozyme, protease inhibitors, assembly inhibitors (e.g., rifampicin), and zidovudine.
  • Further disclosed herein are methods of treating HCMV or other virus infection that is present within the tumor of a subject, e.g., a human. HCMV DNA, RNA and protein have been shown to be present in some human tumors, including malignant glioma (Cobbs CS. Herpesviridae 2:10, 2011), and the presence of the virus is thought to promote the pathogenesis of these cancers. Therefore, inhibition of HCMV gene expression, replication, growth or spread by dual sirtuin antagonists (or, more generally, by simultaneously inhibiting two or more sirtuins) in patients with cancers, where at least a portion of the tumor cells (malignant tumor cells or tumor-associated stromal cells) contain the HCMV genome, is predicted to be therapeutically beneficial. Dual sirtuin inhibitors could be used alone or in combination with other anti-viral or anti-tumor therapeutics. A preferred embodiment of this therapeutic application of dual sirtuin inhibitors would be treatment of malignant glioma, but any tumor containing the HCMV genome in at least a portion of its cells is disclosed herein as a target for this therapy. A second preferred embodiment of this therapeutic application would be treatment of tumors containing the genome of HCMV, but tumors with the genome any virus whose replication can be inhibited by dual sirtuin inhibitors, are disclosed herein as a target for this therapy. A preferred therapeutic application comprises inhibitors of SIRT1 and SIRT2, inhibitors of SIRT1 plus SIRT2 plus another sirtuin, inhibitors of SIRT1 plus one or more sirtuins that do not include SIRT2, inhibitors of SIRT2 plus one or more sirtuins that do not include SIRT1, or a combination of inhibitors of two or more sirtuins that do not include SIRT1 or SIRT2.
  • Embodiments include a pharmaceutical composition including any of the anti-viral drugs herein and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may include at least one of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, human serum albumin, buffer substances, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, waxes, polyethylene glycol, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, talc, magnesium carbonate, kaolin, non-ionic surfactants, edible oils, physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.), or phosphate buffered saline (PBS).
  • The route for administering a drug or pharmaceutical composition may be by any route. The route of administration may be any one or more route including but not limited to oral, injection, topical, enteral, rectal, gastrointestinal, sublingual, sublabial, buccal, epidural, intracerebral, intracerebroventricular, intracisternal, epicutaneous, intradermal, subcutaneous, nasal, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intrathecal, intraperitoneal, intravesical, intravitreal, intracavernous, intravaginal, intrauterine, extra-amniotic, transdermal, intratumoral, and transmucosal.
    • Methods of Increasing Viral Yield
  • Also disclosed herein are methods of increasing virus yield by inhibiting sirtuin activity, e.g., inhibiting one or more of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7. Further contemplated are methods wherein neither SIRT1 nor SIRT2 are inhibited or only one of SIRT1 and SIRT2 are inhibited. In various cases, one or more of SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7 are inhibited.
  • The results herein are the first to show that the yield of HCMV, herpes simplex virus, adenovirus, and influenza virus is induced by inhibition of sirtuins and therefore indicate that reduction of sirtuin protein levels or activity or both would enhance the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny and other viruses that are inhibited by sirtuin activity. Importantly, the results herein are also the first to show that modulation of each of the seven sirtuins can influence viral replication and therefore provide a prediction that inhibition of any one of the different known sirtuin activities will enhance the production of HCMV, herpes simplex virus, adenovirus, and influenza virus progeny.
  • Since production of very different viruses (DNA genome and RNA genome; naked and enveloped) has been enhanced by inhibiting sirtuin activity, it is contemplated that the growth of additional viruses and their attenuated or otherwise modified derivatives also can be enhanced by inhibition of sirtuins. These additional viruses include but are not limited to: polio viruses, hepatitis A virus, rabies virus, measles virus, mumps virus, rubella virus, rotavirus, varicella zoster virus, yellow fever virus, lentiviruses including HIV, retroviruses and adeno-associated virus.
  • Inhibition of sirtuins to increase viral yields can be achieved by contacting a cell with an inhibitor of a sirtuin or inhibitor of sirtuin expression. Inhibition of sirtuin expression can be by RNAi, e.g., contacting one or more siRNA to one or more of the mRNAs encoding sirtuins. Specific siRNAs tested and shown in FIG. 1 are in Table 3.
  • TABLE 3
    Target siRNA Sequence (5′ to 3′) SEQ ID NO
    Sirt1_1 GUGUCAUGGUUCCUUUGCA [dT] [dT]  1
    UGCAAAGGAACCAUGACAC [dT] [dT]  2
    Sirt1_2 CUGUGAAGCUGUACGAGGA [dT] [dT]  3
    UCCUCGUACAGCUUCACAG [dT] [dT]  4
    Sirt1_3 CAACUAUACCCAGAACAUA [dT] [dT]  5
    UAUGUUCUGGGUAUAGUUG [dT] [dT]  6
    Sirt2_1 CUACUCCUGCGUGCUACA [dT] [dT]  7
    UGUAGCAGCGCAGGAGUAG [dT] [dT]  8
    Sirt2_2 GGAGUAACCUCCCUCAUCU [dT] [dT]  9
    AGAUGAGGGAGGUUACUCC [dT] [dT] 10
    Sirt2_3 CGCGUUUCUUCUCCUGUAU [dT] [dT] 11
    AUACAGGAGAAGAAACGCG [dT] [dT] 12
    Sirt3_1 GCUUUCUGUGCCUAGUUGA [dT] [dT] 13
    UCAACUAGGCACAGAAAGC [dT] [dT] 14
    Sirt3_2 CUCAAAGCUGGUUGAAGCU [dT] [dT] 15
    AGCUUCAACCAGCUUUGAG [dT] [dT] 16
    Sirt3_3 GACAAGACCUCAUGCCUGA [dT] [dT] 17
    UCAGGCAUGAGGUCUUGUC [dT] [dT] 18
    Sirt4_1 GGGAUCAUCCUUGCAGGUA [dT] [dT] 19
    UACCUGCAAGGAUGAUCCC [dT] [dT] 20
    Sirt4-2 GAGAAACUCGGAAAGCUGU [dT] [dT] 21
    ACAGCUUUCCGAGUUUCUC [dT] [dT] 22
    Sirt4_3 CUUUGAGCACCUGGGAGAA [dT] [dT] 23
    UUCUCCCAGGUGCUCAAAG [dT] [dT] 24
    Sirt5_1 GUGAGACCCGGCUGGGCAA [dT] [dT] 25
    UUGCCCAGCCGGGUCUCAC [dT] [dT] 26
    Sirt5_2 CAGCAUCCCAGUUGAGAAA [dT] [dT] 27
    UUUCUCAACUGGGAUGCUG [dT] [dT] 28
    Sirt5_3 GAGAUCCAUGGUAGCUUAU [dT] [dT] 29
    AUAAGCUACCAUGGAUCUC [dT] [dT] 30
    Sirt6-1 CUGUCCAUCACGCUGGGUA [dT] [dT] 31
    UACCCAGCGUGAUGGACAG [dT] [dT] 32
    Sirt6_2 CUCACUUUGUUACUUGUUU [dT] [dT] 33
    AAACAAGUAACAAAGUGAG [dT] [dT] 34
    Sirt6_3 CCAAGUGUAAGACGCAGUA [dT] [dT] 35
    UACUGCGUCUUACACUUGG [dT] [dT] 36
    Sirt7_1 GGGAGUACGUGCGGGUGUU [dT] [dT] 37
    AACACCCGCACGUACUCCC [dT] [dT] 38
    Sirt7_2 GACGUAAUCACGUGCUCGA [dT] [dT] 39
    UCGAGCACGUGAUUACGUC [dT] [dT] 40
    Sirt7_3 GACGUCAUGCGGCUCCUCA [dT] [dT] 41
    UGAGGAGCCGCAUGACGUC [dT] [dT] 42
  • A subset of sequences from Table 3 contemplated for use as inhibitors of sirtuin gene expression and increase in virus production are shown in Table 3A, below. The use of these siRNAs and any other siRNA able to inhibit sirtuin expression is contemplated.
  • TABLE 3A
    SEQ
    Target ID NO: siRNA Sequence (5′ to 3′)
    Sirt1_2  3 CUGUGAAGCUGUACGAGGA [dT] [dT]
     4 UCCUCGUACAGCUUCACAG [dT] [dT]
    Sirt2_1  7 CUACUCCUGCGUGCUACA [dT] [dT]
     8 UGUAGCAGCGCAGGAGUAG [dT] [dT]
    Sirt2_3 11 CGCGUUUCUUCUCCUGUAU [dT] [dT]
    12 AUACAGGAGAAGAAACGCG [dT] [dT]
    Sirt3_1 13 GCUUUCUGUGCCUAGUUGA [dT] [dT]
    14 UCAACUAGGCACAGAAAGC [dT] [dT]
    Sirt3_2 15 CUCAAAGCUGGUUGAAGCU [dT] [dT]
    16 AGCUUCAACCAGCUUUGAG [dT] [dT]
    Sirt3_3 17 GACAAGACCUCAUGCCUGA [dT] [dT]
    18 UCAGGCAUGAGGUCUUGUC [dT] [dT]
    Sirt4_1 19 GGGAUCAUCCUUGCAGGUA [dT] [dT]
    20 UACCUGCAAGGAUGAUCCC [dT] [dT]
    Sirt4_2 21 GAGAAACUCGGAAAGCUGU [dT] [dT]
    22 ACAGCUUUCCGAGUUUCUC [dT] [dT]
    Sirt4_3 23 CUUUGAGCACCUGGGAGAA [dT] [dT]
    24 UUCUCCCAGGUGCUCAAAG [dT] [dT]
    Sirt5_1 25 GUGAGACCCGGCUGGGCAA [dT] [dT]
    26 UUGCCCAGCCGGGUCUCAC [dT] [dT]
    Sirt5_2 27 CAGCAUCCCAGUUGAGAAA [dT] [dT]
    28 UUUCUCAACUGGGAUGCUG [dT] [dT]
    Sirt5_3 29 GAGAUCCAUGGUAGCUUAU [dT] [dT]
    30 AUAAGCUACCAUGGAUCUC [dT] [dT]
    Sirt6-1 31 CUGUCCAUCACGCUGGGUA [dT] [dT]
    32 UACCCAGCGUGAUGGACAG [dT] [dT]
    Sirt6_2 33 CUCACUUUGUUACUUGUUU [dT] [dT]
    34 AAACAAGUAACAAAGUGAG [dT] [dT]
    Sirt6_3 35 CCAAGUGUAAGACGCAGUA [dT] [dT]
    36 UACUGCGUCUUACACUUGG [dT] [dT]
    Sirt7_1 37 GGGAGUACGUGCGGGUGUU [dT] [dT]
    38 AACACCCGCACGUACUCCC [dT] [dT]
  • Inhibition of sirtuin expression can be by RNAi, e.g., contacting one or more shRNAs to one or more of the mRNAs encoding sirtuins. Sequences of shRNA for various sirtuin genes are shown in Table 4, below. The use of these shRNAs and any other shRNA able to inhibit sirtuin expression is contemplated.
  • TABLE 4
    SEQ
    Gene Species ID NO shRNA sequence
    Sirt1 H. Sapiens 43 CCGGGCAAAGCCTTTCTGAATCTATCTCGAGATAGATTCAGAAAGGCTTTGCTTTTT
    44 CCGGCCTCGAACAATTCTTAAAGATCTCGAGATCTTTAAGAATTGTTCGAGGTTTTT
    45 CCGGGCGGGAATCCAAAGGATAATTCTCGAGAATTATCCTTTGGATTCCCGCTTTTT
    M. musculus 46 CCGGAGTGAGACCAGTAGCACTAATCTCGAGATTAGTGCTACTGGTCTCACTTTTTTG
    47 CCGGGCCATGTTTGATATTGAGTATCTCGAGATACTCAATATCAAACATGGCTTTTTG
    48 CCGGGAGGGTAATCAATACCTGTTTCTCGAGAAACAGGTATTGATTACCCTCTTTTTG
    Sirt2 H. Sapiens 49 CCGGTATGACAACCTAGAGAAGTACCTCGAGGTACTTCTCTAGGTTGTCATATTTTTG
    50 CCGGCAGAAGACATTGCTTATTGGACTCGAGTCCAATAAGCAATGTCTTCTGTTTTTG
    51 CCGGCCTGTGGCTAAGTAAACCATACTCGAGTATGGTTTACTTAGCCACAGGTTTTTG
    M. musculus 52 CCGGCCTTCGTTCTTTAACCACTTTCTCGAGAAAGTGGTTAAAGAACGAAGGTTTTT
    53 CCGGCCTCTATGCAAACCTGGAGAACTCGAGTTCTCCAGGTTTGCATAGAGGTTTTT
    54 CCGGCGGCTGCTCATTAACAAGGAACTCGAGTTCCTTGTTAATGAGCAGCCGTTTTT
    Sirt3 H. Sapiens 55 CCGGCCCAACGTCACTCACTACTTTCTCGAGAAAGTAGTGAGTGACGTTGGGTTTTTG
    56 CCGGGCGGCTCTACACGCAGAACATCTCGAGATGTTCTGCGTGTAGAGCCGCTTTTTG
    57 CCGGGTGGGTGCTTCAAGTGTTGTTCTCGAGAACAACACTTGAAGCACCCACTTTTTG
    M. musculus 58 CCGGCCTACTCCATATGGCTGACTTCTCGAGAAGTCAGCCATATGGAGTAGGTTTTTG
    59 CCGGAGACAGCTCCAACACGTTTACCTCGAGGTAAACGTGTTGGAGCTGTCTTTTTTG
    60 CCGGGCCCAATGTCACTCACTACTTCTCGAGAAGTAGTGAGTGACATTGGGCTTTTTG
    Sirt4 H. Sapiens 61 CCGGCCCGATTGCAATACTGAACATCTCGAGATGTTCAGTATTGCAATCGGGTTTTT
    62 CCGGCCGTGCTCGAAAGCCTCCATTCTCGAGAATGGAGGCTTTCGAGCACGGTTTTT
    63 CCGGGAACCCTGACAAGGTTGATTTCTCGAGAAATCAACCTTGTCAGGGTTCTTTTT
    M. musculus 64 GTACCGGAGTAAACCACAACTGTCTATGCTCGAGCATAGACAGTTGTGGTTTACTTTTTTTG
    65 CCGGGCAGCATATCCGGAACCTTAACTCGAGTTAAGGTTCCGGATATGCTGCTTTTTG
    66 CCGGTTGACTTTCAGGCCGACAAAGCTCGAGCTTTGTCGGCCTGAAAGTCAATTTTTG
    Sirt5 H. Sapiens 67 CCGGGAGTCCAATTTGTCCAGCTTTCTCGAGAAAGCTGGACAAATTGGACTCTTTTT
    68 CCGGGCTACGAACAGATTCAGGTTTCTCGAGAAACCTGAATCTGTTCGTAGCTTTTT
    69 CCGGCGTCCACACGAAACCAGATTTCTCGAGAAATCTGGTTTCGTGTGGACGTTTTT
    M. musculus 70 CCGGGCAGACAATCTGTTACGTGATCTCGAGATCACGTAACAGATTGTCTGCTTTTTG
    71 CCGGCCAGTTGTGTTGTAGACGAAACTCGAGTTTCGTCTACAACACAACTGGTTTTTG
    72 CCGGCGACAGATTCAGGTTTCATTTCTCGAGAAATGAAACCTGAATCTGTCGTTTTTG
    Sirt6 H. Sapiens 73 CCGGTGGAAGAATGTGCCAAGTGTACTCGAGTACACTTGGCACATTCTTCCATTTTTG
    74 CCGGGCAGTCTTCCAGTGTGGTGTTCTCGAGAACACCACACTGGAAGACTGCTTTTTG
    75 CCGGGCTGGGTACATCGCTGCAGATCTCGAGATCTGCAGCGATGTACCCAGCTTTTTG
    M. musculus 76 CCGGCATGTCCAACACAGCTCCTTTCTCGAGAAAGGAGCTGTGTTGGACATGTTTTTG
    77 CCGGGCATGTTTCGTATAAGTCCAACTCGAGTTGGACTTATACGAAACATGCTTTTTG
    78 CCGGGTTTGACACCACCTTCGAGAACTCGAGTTCTCGAAGGTGGTGTCAAACTTTTTG
    Sirt7 H. Sapiens 79 CCGGGTCCAGCCTGAAGGTTCTAAACTCGAGTTTAGAACCTTCAGGCTGGACTTTTTG
    80 CCGGCGCCAAATACTTGGTCGTCTACTCGAGTAGACGACCAAGTATTTGGCGTTTTT
    81 CCGGGCCTGAAGGTTCTAAAGAAGTCTCGAGACTTCTTTAGAACCTTCAGGCTTTTT
    M. musculus 82 CCGGCCTCCCTCTTTCTACTCCTTACTCGAGTAAGGAGTAGAAAGAGGGAGGTTTTTG
    83 CCGGTGCATCCCTAACAGAGAGTATCTCGAGATACTCTCTGTTAGGGATGCATTTTTG
    84 CCGGCCTGGAGATTCCTGTCTACAACTCGAGTTGTAGACAGGAATCTCCAGGTTTTTG
  • Gene sequences for each of the sirtuins in various species can be found at the Genbank Accession Nos. noted in Table 5, below. As such, siRNA and shRNA that inhibit gene expression of any of the genes referenced in Table 5, as well as sirtuin genes from other species, are specifically contemplated.
  • TABLE 5
    Gene Species Genbank Accession No
    Sirt1 Homo sapiens NM 012238.4
    Mus musculus NM 019812.2
    Canis lupus XM 546130.3
    familiaris
    Cricetulus griseus XM 003501011.1 (Sirt1-like)
    Sirt2 Homo sapiens NM 012237.3
    Mus musculus NM 022432.4
    Canis lupus XM 850289.2
    familiaris
    Sirt3 Homo sapiens NM 012239.5
    Mus musculus NM 001127351.1
    Canis lupus XM 850716.2
    familiaris
    Sirt4 Homo sapiens NM 012240.2
    Mus musculus NM 001167691.1
    Canis lupus XM 858071.2
    familiaris
    Cricetulus griseus XM 003495917.1 (Sirt4-like)
    Sirt5 Homo sapiens NM 012241.4
    Mus musculus NM 178848.3
    Canis lupus XM 535891.3
    familiaris
    Cricetulus griseus XM 003497937.1 (Sirt5-like)
    Sirt6 Homo sapiens NM 016539.2
    Mus musculus NM 181586.3
    Canis lupus XM 542163.3
    familiaris
    Cricetulus griseus XM 003506436.1
    Sirt7 Homo sapiens NM 016538.2
    Mus musculus NM 153056.2
    Canis lupus XM 540490.3
    familiaris
    Cricetulus griseus XM 003496941.1 (Sirt7-like)
    • RNAi
  • RNA interference (RNAi), a post-transcriptional process triggered by the introduction of double-stranded RNA, leads to gene silencing in a sequence-specific manner. In many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. The RNAi compounds are often referred to as short interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs). It has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the siRNAs which are the potent inducers of RNAi (Tijsterman et al., Science, 2002, 295, 694-697). RNAi compounds (i.e., single- or double-stranded RNA or RNA-like compounds) and single-stranded RNase H-dependent antisense compounds bind to their RNA target by base pairing (i.e., hybridization) and induce site-specific cleavage of the target RNA by specific RNAses; i.e., both are antisense mechanisms (Vickers et al., 2003, J. Biol. Chem., 278, 7108-7118). Double-stranded ribonucleases (dsRNases) such as those in the RNase III and ribonuclease L family of enzymes also play a role in RNA target degradation. Double-stranded ribonucleases and oligomeric compounds that trigger them are further described in U.S. Pat. Nos. 5,898,031 and 6,107,094.
  • In order to obtain long-term gene silencing, expression vectors that continually express siRNAs or shRNAs in stably transfected mammalian cells can be used (Brummelkamp et al., Science 296: 550-553, 2002; Lee et al., Nature Biotechnol. 20:500-505, 2002; Miyagishi, M, and Taira, K. Nature Biotechnol. 20:497-500, 2002; Paddison, et al., Genes & Dev. 16:948-958, 2002; Paul et al., Nature Biotechnol. 20:505-508, 2002; Sui, Proc. Natl. Acad. Sci. USA 99(6):5515-5520, et al., 2002; Yu et al., Proc. Natl. Acad. Sci. USA 99(9):6047-6052, 2002). Many of these plasmids have been engineered to express shRNAs lacking poly (A) tails. Transcription of shRNAs can be initiated at a polymerase III (pol III) promoter and is believed to be terminated at position 2 of a 4-5-thymine transcription termination site. Upon expression, shRNAs are thought to fold into a stem-loop structure with 3′ UU-overhangs. Subsequently, the ends of these shRNAs are processed, converting the shRNAs into ˜21 nt siRNA-like molecules. The siRNA-like molecules can, in turn, bring about gene-specific silencing in the transfected mammalian cells.
  • Interfering RNAs are therefore double stranded oligonucleotide agents that have complementarity to (i.e., are able to hybridize with) a portion of the target RNA (generally messenger RNA (mRNA)). Generally, such complementarity is 100%, but can be less if desired, such as about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 70%, about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% as long as conditions permit hybridization of the siRNA to the desired target. By way of sample and without limitation, 19 bases out of 21 bases may be base-paired. Thus, it will be understood that an oligonucleotide used in the methods need not be 100% complementary to a desired target nucleic acid in order for the siRNA to hybridize to the target. Moreover, oligonucleotides may hybridize to each other over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). Percent complementarity between any given oligonucleotide can be determined routinely using BLAST programs (Basic Local Alignment Search Tools) and PowerBLAST programs known in the art (Altschul et al., 1990, J. Mol. Biol., 215: 403-410; Zhang and Madden, 1997, Genome Res., 7: 649-656).
  • In some aspects, where selection of a target which differs from other non-target sequence variants by a small number of nucleotides is desired, 100% complementarity to the target sequence is required in order to effectively discern the target sequence from the other non-target sequences. When selecting between targets with little sequence difference, choice of length is also an important factor because it is the other factor involved in the percent complementary and the ability to differentiate between target and n on-target sequences.
  • “Hybridization” means an interaction between two or three strands of nucleic acids by hydrogen bonds in accordance with the rules of Watson-Crick DNA complementarity, Hoogstein binding, or other sequence-specific binding known in the art. Hybridization can be performed under different stringency conditions known in the art.
  • The term “RNA” includes duplexes of two separate strands, as well as single, triple, or quadruple stranded structures. An example of a single strand RNA is an RNA with a hairpin loop. An inhibitory RNA sequence needs to be of sufficient length to bring the small interfering RNA and target RNA together through complementary base-pairing interactions. The RNA useful in the methods disclosed herein may be of varying lengths. The RNA, as disclosed herein, comprises a domain in a single strand of the duplex sufficiently complementary to a sequence in a target polynucleotide to permit hybridization of the single strand to the target polynucleotide under appropriate conditions, and hybridization of the single stranded domain of the duplex to the sequence in the target polynucleotide creates a substrate site recognized by a polypeptide. The length of this single stranded domain is in some aspects greater than or equal to ten nucleotides and of sufficient length to hybridize with the target RNA; specifically 10-100 nucleotides; more specifically any integer between 10 and 80 nucleotides, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100. By “sufficient length” is meant an oligonucleotide of greater than or equal to 10 nucleotides that is of a length great enough to provide the intended function under the expected condition.
  • As used herein, the term “target” or “target polynucleotide” refers to a polynucleotide against which a given RNA can be directed.
  • As used herein, “duplex” refers to a region in two complementary or substantially complementary polynucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a stabilized duplex between polynucleotide strands that are complementary or substantially complementary. For example, a polynucleotide strand having 21 nucleotide units can base pair with another polynucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex” has 19 base pairs. The remaining bases may, for example, exist as 5′ and 3′ overhangs. Further, within the duplex, 100% complementarity is not required; substantial complementarity is allowable within a duplex. Substantial complementarity refers to 75% or greater complementarity. For example, a mismatch in a duplex consisting of 19 base pairs results in 94.7% complementarity, rendering the duplex substantially complementary.
  • RNA may be polymerized in vitro, recombinant RNA, contain chimeric sequences, or derivatives of these groups. The RNA contains, in various embodiments, ribonucleotides, deoxyribonucleotides, synthetic nucleotides, or any suitable combination such that expression of the target gene is inhibited.
  • A delivered RNA can stay within the cytoplasm or nucleus. The RNA can be delivered to a cell to inhibit expression of an endogenous or exogenous nucleotide sequence or protein or to affect a specific physiological characteristic not naturally associated with the cell.
  • A RNA can be delivered to a cell in order to produce a cellular change that is therapeutic. The delivery of RNA or other genetic material for therapeutic purposes (the art of improving health in an animal including treatment or prevention of disease) is called gene therapy. The RNA can be delivered either directly to the organism in situ or indirectly by transfer to a cell ex vivo that is then transplanted into the organism. Entry into the cell is required for the RNA to block the production of a protein or to decrease the amount of a RNA. Polynucleotide sequences contemplated by the present disclosure are further described below.
    • RNA Features and Modifications
  • The term “nucleotide” or its plural as used herein is interchangeable with modified forms as discussed herein and otherwise known in the art. In certain instances, the art uses the term “nucleobase” which embraces naturally-occurring nucleotides as well as modifications of nucleotides that can be polymerized. Thus, nucleotide or nucleobase means the naturally occurring nucleobases adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U) as well as non-naturally occurring nucleobases such as xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N′,N′-ethano-2,6-diaminopurine, 5-methylcytosine (mC), 5-(C3-C6)-alkynyl-cytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-tr-iazolopyridin, isocytosine, isoguanine, inosine and the “non-naturally occurring” nucleobases described in Benner et al., U.S. Pat. No. 5,432,272 and Susan M. Freier and Karl-Heinz Altmann, 1997, Nucleic Acids Research, vol. 25: pp 4429-4443. The term “nucleobase” also includes not only the known purine and pyrimidine heterocycles, but also heterocyclic analogues and tautomers thereof. Further naturally and non-naturally occurring nucleobases include those disclosed in U.S. Pat. No. 3,687,808 (Merigan, et al.), in Chapter 15 by Sanghvi, in Antisense Research and Application, Ed. S. T. Crooke and B. Lebleu, CRC Press, 1993, in Englisch et al., 1991, Angewandte Chemie, International Edition, 30: 613-722 (see especially pages 622 and 623, and in the Concise Encyclopedia of Polymer Science and Engineering, J. I. Kroschwitz Ed., John Wiley & Sons, 1990, pages 858-859, Cook, Anti-Cancer Drug Design 1991, 6, 585-607, each of which are hereby incorporated by reference in their entirety). In various aspects, polynucleotides also include one or more “nucleosidic bases” or “base units” which include compounds such as heterocyclic compounds that can serve like nucleobases, including certain “universal bases” that are not nucleosidic bases in the most classical sense but serve as nucleosidic bases. Universal bases include 3-nitropyrrole, optionally substituted indoles (e.g., 5-nitroindole), and optionally substituted hypoxanthine. Other desirable universal bases include, pyrrole, diazole or triazole derivatives, including those universal bases known in the art.
  • Polynucleotides may also include modified nucleobases. A “modified base” is understood in the art to be one that can pair with a natural base (e.g., adenine, guanine, cytosine, uracil, and/or thymine) and/or can pair with a non-naturally occurring base. Exemplary modified bases are described in EP 1 072 679 and WO 97/12896, the disclosures of which are incorporated herein by reference. Modified nucleobases include without limitation, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified bases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzox-azin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified bases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Additional nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 1991, Angewandte Chemie, International Edition, 30: 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993. Certain of these bases are useful for increasing the binding affinity and include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are, in certain aspects combined with 2′-O-methoxyethyl sugar modifications. See, U.S. Pat. No. 3,687,808, U.S. Pat. Nos. 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; 5,750,692 and 5,681,941, the disclosures of which are incorporated herein by reference.
  • Methods of making polynucleotides of a predetermined sequence are well-known. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed. 1989) and F. Eckstein (ed.) Oligonucleotides and Analogues, 1st Ed. (Oxford University Press, New York, 1991). Solid-phase synthesis methods are preferred for both polyribonucleotides and polydeoxyribonucleotides (the well-known methods of synthesizing DNA are also useful for synthesizing RNA). Polyribonucleotides can also be prepared enzymatically. Non-naturally occurring nucleobases can be incorporated into the polynucleotide, as well. See, e.g., U.S. Pat. No. 7,223,833; Katz, J. Am. Chem. Soc., 74:2238 (1951); Yamane, et al., J. Am. Chem. Soc., 83:2599 (1961); Kosturko, et al., Biochemistry, 13:3949 (1974); Thomas, J. Am. Chem. Soc., 76:6032 (1954); Zhang, et al., J. Am. Chem. Soc., 127:74-75 (2005); and Zimmermann, et al., J. Am. Chem. Soc., 124:13684-13685 (2002).
  • Modified polynucleotides are contemplated for functionalizing nanoparticles wherein both one or more sugar and/or one or more internucleotide linkage of the nucleotide units in the polynucleotide is replaced with “non-naturally occurring” groups. In one aspect, this embodiment contemplates a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of a polynucleotide is replaced with an amide containing backbone. See, for example U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, and Nielsen et al., Science, 1991, 254, 1497-1500, the disclosures of which are herein incorporated by reference.
  • Other linkages between nucleotides and unnatural nucleotides contemplated for the disclosed polynucleotides include those described in U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920; U.S. Patent Publication No. 20040219565; International Patent Publication Nos. WO 98/39352 and WO 99/14226; Mesmaeker et. al., Current Opinion in Structural Biology 5:343-355 (1995) and Susan M. Freier and Karl-Heinz Altmann, Nucleic Acids Research, 25:4429-4443 (1997), the disclosures of which are incorporated herein by reference.
  • Specific examples of polynucleotides include those containing modified backbones or non-natural internucleoside linkages. Polynucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Modified polynucleotides that do not have a phosphorus atom in their internucleoside backbone are considered to be within the meaning of “polynucleotide.”
  • Modified polynucleotide backbones containing a phosphorus atom include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage. Also contemplated are polynucleotides having inverted polarity comprising a single 3′ to 3′ linkage at the 3′-most internucleotide linkage, i.e. a single inverted nucleoside residue which may be abasic (the nucleotide is missing or has a hydroxyl group in place thereof). Salts, mixed salts and free acid forms are also contemplated.
  • Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, the disclosures of which are incorporated by reference herein.
  • Modified polynucleotide backbones that do not include a phosphorus atom have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages; siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts. In still other embodiments, polynucleotides are provided with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and including —CH2—NH—O—CH2—, —CH2—N(CH3)—O—CH2—, —CH2—O—N(CH3)—CH2—, —CH2—N(CH3)—N(CH3)—CH2— and —O—N(CH3)—CH2—CH2— described in U.S. Pat. Nos. 5,489,677, and 5,602,240. See, for example, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, the disclosures of which are incorporated herein by reference in their entireties.
  • In various forms, the linkage between two successive monomers in the oligo consists of 2 to 4, desirably 3, groups/atoms selected from —CH2—, —O—, —S—, —NRH—, >C═O, >C═NRH, >C═S, —Si(R″)2—, —SO—, —S(O)2—, —P(O)2—, —PO(BH3)—, —P(O,S)—, —P(S)2—, —PO(R″)—, —PO(OCH3)—, and —PO(NHRH)—, where RH is selected from hydrogen and C1-4-alkyl, and R″ is selected from C1-6-alkyl and phenyl. Illustrative examples of such linkages are —CH2—CH2—CH2—, —CH2—CO—CH2—, —CH2—CHOH—CH2—, —O—CH2-O—, —O—CH2-CH2-, —O—CH2-CH=(including R5 when used as a linkage to a succeeding monomer), —CH2—CH2—O—, —NRH—CH2—CH2—, —CH2—CH2—NRH—, —CH2—NRH—CH2—, —O—CH2—CH2—NRH—, —NRH—CO—O—, —NRH—CO—NRH—, —NRH—CS—NRH—, —NRH—C(═NRH)—NRH—, —NRH—CO—CH2—NRH—O—CO—O—, —O—CO—CH2—O—, —O—CH2—CO—O—, —CH2—CO—NRH—, —O—CO—NRH—, —NRH—CO—CH2—, —O—CH2—CO—NRH—, —O—CH2—CH2—NRH—, —CH═N—O—, —CH2—NRH—O—, —CH2—O—N=(including R5 when used as a linkage to a succeeding monomer), —CH2—O—NRH—, —CO—NRH—CH2—, —CH2—NRH—O—, —CH2—NRH—CO—, —O—NRH—CH2—, —O—NRH, —O—CH2—S—, —S—CH2—O—, —CH2—CH2—S—, —O—CH2—CH2—S—, —S—CH2—CH=(including R5 when used as a linkage to a succeeding monomer), —S—CH2—CH2—, —S—CH2—CH2—O—, —S—CH2—CH2—S—, —CH2—S—CH2—, —CH2—SO—CH2—, —CH2—SO2—CH2—, —O—SO—O—, —O—S(O)2—O—, —O—S(O)2—CH2—, —O—S(O)2—NRH—, —NRH—S(O)2—CH2—; —O—S(O)2—CH2—, —O—P(O)2—O—, —O—P(O,S)—O—, —O—P(S)2—O—, —S—P(O)2—O—, —S—P(O,S)—O—, —S—P(S)2—O—, —O—P(O)2—S—, —O—P(O,S)—S—, —O—P(S)2—S—, —S—P(O)2—S—, —S—P(O,S)—S—, —S—P(S)2—S—, —O—PO(R″)—O—, —O—PO(OCH3)—O—, —O—PO(OCH2CH3)—O—, —O—PO(OCH2CH2S—R)—O—, —O—PO(BH3)—O—, —O—PO(NHRN)—O—, —O—P(O)2—NRH H—, —NRH—P(O)2—O—, —O—P(O,NRH)—O—, —CH2—P(O)2—O—, —O—P(O)2—CH2—, and —O—Si(R″)2—O—; among which —CH2—CO—NRH—, —CH2—NRH—O—, —S—CH2—O—, —O—P(O)2—O—O—P(—O,S)—O—, —O—P(S)2—O—, —NRH P(O)2—O—, —O—P(O,NRH)—O—, —O—PO(R″)—O—, —O—PO(CH3)—O—, and —O—PO(NHRN)—O—, where RH is selected form hydrogen and C1-4-alkyl, and R″ is selected from C1-6-alkyl and phenyl, are contemplated. Further illustrative examples are given in Mesmaeker et. al., 1995, Current Opinion in Structural Biology, 5: 343-355 and Susan M. Freier and Karl-Heinz Altmann, 1997, Nucleic Acids Research, vol 25: pp 4429-4443.
  • Still other modified forms of polynucleotides are described in detail in U.S. Patent Application No. 20040219565, the disclosure of which is incorporated by reference herein in its entirety.
  • Modified polynucleotides may also contain one or more substituted sugar moieties. In certain aspects, polynucleotides comprise one of the following at the 2′ position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Other embodiments include O[(CH2)nO]mCH3, O(CH2)nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON[(CH2)nCH3]2, where n and m are from 1 to about 10. Other polynucleotides comprise one of the following at the 2′ position: C1 to C10 lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a polynucleotide, or a group for improving the pharmacodynamic properties of a polynucleotide, and other substituents having similar properties. In one aspect, a modification includes 2′-methoxyethoxy (2′-O—CH2CH2OCH3, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., 1995, Helv. Chim. Acta, 78: 486-504) i.e., an alkoxyalkoxy group. Other modifications include 2′-dimethylaminooxyethoxy, i.e., a O(CH2)2ON(CH3)2 group, also known as 2′-DMAOE, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethyl-amino-ethoxy-ethyl or 2′-DMAEOE), i.e., 2′-O—CH2—O—CH2—N(CH3)2.
  • Still other modifications include 2′-methoxy (2′-O—CH3), 2′-aminopropoxy (2′-OCH2CH2CH2NH2), 2′-allyl (2′-CH2—CH═CH2), 2′-O-allyl (2′-O—CH2—CH═CH2) and 2′-fluoro (2′-F). The 2′-modification may be in the arabino (up) position or ribo (down) position. In one aspect, a 2′-arabino modification is 2′-F. Similar modifications may also be made at other positions on the polynucleotide, for example, at the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked polynucleotides and the 5′ position of 5′ terminal nucleotide. Polynucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. See, for example, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, the disclosures of which are incorporated by reference in their entireties herein.
  • In one aspect, a modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2′-hydroxyl group is linked to the 3′ or 4′ carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is in certain aspects a methylene (—CH2—)n group bridging the 2′ oxygen atom and the 4′ carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226, the disclosures of which are incorporated herein by reference.
    • Chimerics
  • It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. These “chimeric” antisense compounds typically contain at least one region including a modification as described herein, while the remainder of the oligonucleotide remains “unmodified.”
  • In certain aspects, the modification confers increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. In other aspects the modification serves as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNAse H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNAseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
  • Chimeric compounds may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. See, for example, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, the disclosures of which are incorporated herein by reference in their entireties.
    • RNA Sequences and Hybridization
  • In some aspects, the disclosure provides methods of targeting specific nucleic acids, e.g., specific RNAs coded by sirtuin genes as disclosed in Table 5. The target nucleic acid may be in cells, tissue samples, or biological fluids, as also known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed. 1989) and B. D. Hames and S. J. Higgins, Eds., Gene Probes 1 (IRL Press, New York, 1995).
  • The terms “start codon region” and “translation initiation codon region” refer to a portion of a mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation initiation codon. Similarly, the terms “stop codon region” and “translation termination codon region” refer to a portion of such a mRNA or gene that encompasses contiguous nucleotides in either direction (i.e., 5′ or 3′) from a translation termination codon. Consequently, the “start codon region” (or “translation initiation codon region”) and the “stop codon region” (or “translation termination codon region”) are all regions which may be targeted effectively with the oligonucleotides on the functionalized nanoparticles.
  • Other target regions include the 5′ untranslated region (5′UTR), the portion of an mRNA in the 5′ direction from the translation initiation codon, including nucleotides between the 5′ cap site and the translation initiation codon of a mRNA (or corresponding nucleotides on the gene), and the 3′ untranslated region (3′UTR), the portion of a mRNA in the 3′ direction from the translation termination codon, including nucleotides between the translation termination codon and 3′ end of a mRNA (or corresponding nucleotides on the gene). The 5′ cap site of a mRNA comprises an N7-methylated guanosine residue joined to the 5′-most residue of the mRNA via a 5′-5′ triphosphate linkage. The 5′ cap region of a mRNA is considered to include the 5′ cap structure itself as well as the first 50 nucleotides adjacent to the cap site.
    • Other Methods of Blocking or Reducing Sirtuin Activity
  • Also disclosed herein are methods of increasing virus yield by inhibiting sirtuin activity by additional methods. For example, dominant negative proteins can be used to inhibit sirtuin activity. Dominant negative proteins are proteins that interfere with the activity of their normal counterparts. Dominant negative proteins no longer mediate all aspects of a protein's normal function, and also inhibit the normal functioning of the corresponding wild-type protein or the function of other proteins with which they interact. Dominant negative proteins can be introduced into cells by a variety of methods well known in the art.
  • Also disclosed herein are methods of increasing virus yield by using cells or tissues (or in the case of chickens, eggs) isolated from transgenic animals in which one or more sirtuin genes have been deleted or otherwise partially or completely inactivated. Transgenic animals can be produced by methods well known in the art.
  • Also disclosed herein are methods of increasing virus yield by introducing mutations into cells that partially or completely inactivate the expression one or more sirtuins. Various methods for directing mutations to specific targets within cells are well known in the art, e.g., by using engineered zinc-finger endonucleases (Sander et al., Nat Methods 8, 67-9, 2011) or by using TALENS (Cermak et al., Nucl Acids Res 39, e82).
  • The references cited throughout this application, are incorporated for all purposes apparent herein and in the references themselves as if each reference was fully set forth. For the sake of presentation, specific ones of these references are cited at particular locations herein. A citation of a reference at a particular location indicates a manner(s) in which the teachings of the reference are incorporated. However, a citation of a reference at a particular location does not limit the manner in which all of the teachings of the cited reference are incorporated for all purposes.
  • Any single embodiment herein may be supplemented with one or more element from any one or more other embodiment herein.
  • It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but is intended to cover all modifications which are within the spirit and scope of the invention as defined by the appended claims; the above description; and/or shown in the attached drawings.
    • EXAMPLES OF THE EMBODIMENTS
  • Paragraph 1. A composition comprising a one or more sirtuin agonist.
  • Paragraph 2. The composition of paragraph 1, wherein the one or more sirtuin agonist increases the activity of any, a subset of, or all of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 or SIRT7.
  • Paragraph 3. The composition of paragraph 1 or 2, wherein the one or more sirtuin agonist is selected from the group consisting of small molecules, nucleic acids, proteins, peptide based activators, CAY10602, Resveratrol, Quercetin, Butein, Piceatannol, Isoiquiritigenin, Fisetin, Pyrroloquinoxaline, Oxazolopyridine, SRT1720, SRT1460, SRT2379 and SRT2104.
  • Paragraph 4. The composition of any of the preceding paragraphs, including any one or more of CAY10602, Resveratrol, Quercetin, Butein, Piceatannol, Isoiquiritigenin, Fisetin, Pyrroloquinoxaline, Oxazolopyridine, SRT1720, SRT1460, SRT2379 or SRT2104.
  • Paragraph 5. A composition comprising a sirtuin gene expression activator.
  • Paragraph 6. A composition comprising a sirtuin allosteric activator.
  • Paragraph 7. The composition of any of the preceding paragraphs, wherein the agonist includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; the expression activator includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; and the allosteric activator includes at least one of a small molecule, a nucleic acid, a protein, or a peptide.
  • Paragraph 8. A composition comprising at least one of a sirtuin agonist, a sirtuin gene expression activator, or a sirtuin activator of any of the preceding paragraphs.
  • Paragraph 9. A composition comprising one or more sirtuin antagonist.
  • Paragraph 10. The composition of paragraph 9 wherein the one or more sirtuin antagonists decreases the activity of both of SIRT1 and SIRT2.
  • Paragraph 11. The composition of paragraph 9 or 10 wherein the sirtuin antagonist is selected from the group consisting of small molecules, nucleic acids, proteins, peptide based activators alone or in combination with at least one of Cambinol, Tenovin 1, Tenovin 6, Salermide and Sirtinol.
  • Paragraph 12. A composition comprising one or more sirtuin gene expression inhibitors.
  • Paragraph 13. A composition comprising one or more sirtuin competitive inhibitors.
  • Paragraph 14. The composition of any of paragraphs 9-13, wherein the antagonist includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; the expression inhibitor includes at least one of a small molecule, a nucleic acid, a protein, or a peptide; and the competitive inhibitor includes at least one of a small molecule, a nucleic acid, a protein, or a peptide.
  • Paragraph 15. A composition comprising at least one of a sirtuin antagonist, a sirtuin gene expression inhibitor, or a sirtuin competitive inhibitor of any of the preceding paragraphs.
  • Paragraph 16. A pharmaceutical composition comprising the composition of any of paragraphs 1-15 and a pharmaceutically acceptable carrier.
  • Paragraph 17. The pharmaceutical composition of paragraph 16, wherein the pharmaceutically acceptable carrier includes at least one substance selected from the group consisting of ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, human serum albumin, buffer substances, phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts, electrolytes, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, waxes, polyethylene glycol, starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, talc, magnesium carbonate, kaolin, non-ionic surfactants, edible oils, physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) and phosphate buffered saline (PBS).
  • Paragraph 18. A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient.
  • Paragraph 19. A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by any one or more virus.
  • Paragraph 20. A method of treating disease comprising administering the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by a single virus.
  • Paragraph 21. A method of treating disease comprising providing the composition of any of paragraphs 1-15 or the pharmaceutical composition of any of paragraphs 16-17 to a patient, wherein the disease is caused by HCMV.
  • Paragraph 22. A method of treating disease comprising induction of sirtuin gene expression in a patient.
  • Paragraph 23. A method of treating disease comprising inhibition of sirtuin gene expression in a patient.
  • Paragraph 24. The method of paragraph 22 or 23, wherein the expression of any one or more of SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 or SIRT7 is induced or inhibited, respectively.
  • Paragraph 25. A method of inhibiting virus production comprising contacting the virus with a sirtuin agonist.
  • Paragraph 26. The method of paragraph 25, wherein the sirtuin agonist is a polyhydroxy chalcone, polyhydroxy flavonoid, polyhydroxy stilbene, or a combination thereof.
  • Paragraph 27. The method of paragraph 25, wherein the agonist has a structure
  • Figure US20130338178A1-20131219-C00174
  • wherein
    • R1 is H or OH and R2 is
  • Figure US20130338178A1-20131219-C00175
    • or R1 is
  • Figure US20130338178A1-20131219-C00176
    • and R2 is H or OH;
  • the dashed line indicates an optional double bond;
    x and y are each 0, 1, 2, 3, 4, or 5, and x+y≧1;
    w and z are each 0, 1, 2, 3, 4, or 5, and w+z≧1; and
    n and m are each 0, 1, 2, 3, 4, or 5, n+m≧1,
    or a salt or ester thereof.
  • Paragraph 28. The method of paragraph 27, wherein the dashed line is a double bond.
  • Paragraph 29. The method of paragraph 27 or 28, wherein R1 is H or OH and R2 is
  • Figure US20130338178A1-20131219-C00177
  • Paragraph 30. The method of paragraph 27 or 28, wherein R2 is H or OH and R1 is
  • Figure US20130338178A1-20131219-C00178
  • Paragraph 31. The method of paragraph 25, wherein the sirtuin agonist is resveratrol, quercetin, rutin, butein, piceatannol, isoliquiritigenin, fisetin, fustin, sulfuretin, genistein, daidzein, taxifolin, aromadedrin, a combination thereof, or a salt or ester thereof.
  • Paragraph 32. The method of paragraph 25, wherein the sirtuin agonist is CAY10602, pyrroloquinoxaline, oxazolopyridine, SRT1720, SRT1460, SRT2379, SRT2104, or GSK184072.
  • Paragraph 33. The method of paragraph 25, wherein the sirtuin agonist is 3,5-dihydroxy-4′-chloro-trans-stilbene, dipyridamole, 3,5-dihydroxy-4′ethyl-trans-stilbene, 3,5-dihydroxy-4′-isopropyl-trans-stilbene, 3,5-dihydroxy-4′-methyl-trans-stilbene, resveratrol, 3,5-dihydroxy-4′thiomethyl-trans-stilbene, 3,5-dihydroxy-4′-carbomethoxy-trans-stilbene, isoliquiritgenin, 3,5-dihydro-4′nitro-trans-stilbene, 3,5-dihydroxy-4′azido-trans-stilbene, piceatannol, 3-methoxy-5-hydroxy-4′acetamido-trans-stilbene, 3,5-dihydroxy-4′acetoxy-trans-stilbene, pinosylvin, fisetin, (E)-1-(3,5-dihydrophenyl)-2-(4-pyridyl)ethene, (E)-1-(3,5-dihydrophenyl)-2-(2-napthyl)ethene, 3,5-dihydroxy-4′-acetamide-trans-stilbene, butein, quercetin, 3,5-dihydroxy-4′-thioethyl-trans-stilbene), 3,5-dihydroxy-4′carboxy-trans-stilbene, 3,4′-dihydroxy-5-acetoxy-trans-stilbene, or a combination thereof.
  • Paragraph 34. The method of paragraph 25, wherein the sirtuin agonist is trans-stilbene, cis-stilbene, resveratrol, piceatannol, rhapontin, deoxyrhapontin, butein, chalcon; isoliquirtigen; butein; 4,2′,4′-trihydroxychalcone; 3,4,2′,4′,6′-pentahydroxychalcone; flavone, morin, fisetin; luteolin; quercetin; kaempferol; apigenin; gossypetin; myricetin; 6-hydroxyapigenin; 5-hydroxyflavone; 5,7,3′,4′,5′-pentahydroxyflavone; 3,7,3′,4′,5′-pentahydroxyflavone; 3,6,3′,4′-tetrahydroxyflavone; 7,3′,4′,5′-tetrahydroxyflavone; 3,6,2′,4′-tetrahydroxyflavone; 7,4′-dihydroxyflavone; 7,8,3′,4′-tetrahydroxyflavone; 3,6,2′,3′-tetrahydroxyflavone; 4′-hydroxyflavone; 5-hydroxyflavone; 5,4′-dihydroxyflavone; 5,7-dihydroxyflavone; daidzein, genistein, naringenin; flavanone; 3,5,7,3′,4′-pentahydroxyflavanone; pelargonidin chloride, cyanidin chloride, delphinidin chloride, (−)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (−)-gallocatechin (Hydroxy Sites: 3,5,7,3′,4′,5′) (+)-catechin (Hydroxy Sites: 3,5,7,3′,4′); (+)-epicatechin (Hydroxy Sites: 3,5,7,3′,4′); Hinokitiol (b-Thujaplicin; 2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one); L-(+)-Ergothioneine ((S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethanam-inium inner salt); Caffeic Acid Phenyl Ester; MCI-186 (3-Methyl-1-phenyl-2-pyrazolin-5-one); HBED (N,N′-Di-(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid.H2O); Ambroxol (trans-4-(2-Amino-3,5-dibromobenzylamino)cyclohexane-HCl; and U-83836E ((−)-2-((4-(2,6-di-1-Pyrrolidinyl-4-pyrimidinyl)-1-piperzainyl)m-ethyl)-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol.2HCl); .beta.-1′-5-methyl-nicotinamide-2′-deoxyribose; .beta.-D-1′-5-methyl-nicotinamide-2′-deoxyribofuranoside; .beta.-1′-4,5-dimethyl-nicotinamide-2′-de-oxyribose; or .beta.-D-1′-4,5-dimethyl-nicotinamide-2′-deoxyribofuranoside; dipyridamole, ZM 336372 (3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamide), camptothecin, coumestrol, nordihydroguaiaretic acid, esculetin, SRT-1720 (Sirtris), SRT-1460 (Sirtris), SRT-2183 (Sirtris), analogs thereof, or combinations thereof.
  • Paragraph 35. The method of any one of paragraphs 25-34, wherein the sirtuin is SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, or a combination thereof.
  • Paragraph 36. The method of any one of paragraphs 25-35, wherein the agonist activates only one sirtuin.
  • Paragraph 37. The method of any one of paragraphs 25-36, wherein the contacting comprising administering the agonist to a subject suffering from a viral infection.
  • Paragraph 38. The method of paragraph 37, wherein the subject is human.
  • Paragraph 39. The method of any one of paragraphs 25-38, wherein the virus is HCMV.
  • Paragraph 40. A method of inhibiting virus production comprising contacting the virus with a SIRT1/SIRT2 dual inhibitor.
  • Paragraph 41. The method of paragraph 40, wherein the SIRT1/SIRT2 dual inhibitor is cambinol, salermide, tenovin-6, tenovin-1, or a combination thereof.
  • Paragraph 42. The method of paragraph 40 or 41, wherein the virus inactivates p53 during viral replication.
  • Paragraph 43. The method of any one of paragraphs 40-42, wherein the virus is HCMV.
  • Paragraph 44. The method of any one of paragraphs 40-42, wherein the virus is human papilloma virus, HSV1, Ad5, FluA, human adenovirus, hepatitis B virus, hepatitis C virus, or HIV.
  • Paragraph 45. The method of any one of paragraphs 40-42, wherein the virus is Adenoviridae (Adenovirus, with E1B-55K as a p53 inactivating protein); Hepadnaviridae (HBV, with X protein as a p53 inactivating protein); Herpesviridae (EBV, with LMP1 as a p53 inactivating protein; HSV-1 with ICP0 as a p53 inactivating protein; HCMV, with IE1 as a p53 inactivating protein; KSHV with LANA as a p53 inactivating protein); Flaviviridae (HCV with NS5A as a p53 inactivating protein); Orthomixoviridae (Influenza A with NS1 as a p53 inactivating protein); Papillomaviridae (HPV with E6 as a p53 inactivating protein); Polyomaviridae (SV40 with Large T-antigen as a p53 inactivating protein; JC virus with Large T-antigen as a p53 inactivating protein; BK virus with Large T antigen as a p53 inactivating protein); or Retroviridae (HIV with Tat as a p53 inactivating protein).
  • Paragraph 46. The method of any one of paragraphs 25-45, further comprising contacting the virus with a second agent.
  • Paragraph 47. The method of paragraph 46, wherein the second agent is a second SIRT1/SIRT2 dual inhibitor or a second sirtuin agonist.
  • Paragraph 48. The method of paragraph 46, wherein the second agent is an antiviral agent.
  • Paragraph 49. The method of paragraph 48, wherein the antiviral agent is acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, immunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor, lamivudine, lopinavir, loviride, mk-0518, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleotide and/or nucleoside analogues, oseltamivir, penciclovir, peramivir, podophyllotoxin, rimantadine, ritonavir, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, morpholino oligonucleotides, ribozyme, protease inhibitors, an assembly inhibitor (e.g., rifampicin), zidovudine, or a combination thereof.

Claims (26)

1. A method of inhibiting virus production comprising contacting a virus-infected cell with one or more inhibitors of two or more sirtuins, wherein the sirtuins are selected from SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7.
2.-10. (canceled)
11. A method of inhibiting virus production comprising contacting a virus-infected cell with a SIRT1 inhibitor and a SIRT2 inhibitor.
12. The method of claim 11, wherein the SIRT1 inhibitor and the SIRT2 inhibitor are a dual SIRT1/SIRT2 inhibitor.
13. (canceled)
14. The method of claim 12, wherein the dual SIRT1/SIRT2 inhibitor is cambinol, salermide, tenovin-6, tenovin-1, or a combination thereof.
15.-20. (canceled)
21. The method of claim 1, wherein the virus is HCMV, human papilloma virus, HSV1, FluA, adenovirus, influenza virus, hepatitis B virus, hepatitis C virus, or HIV.
22. The method of claim 11, wherein the virus is Adenoviridae; Hepadnaviridae; Herpesviridae; Flaviviridae; Orthomixoviridae; Papillomaviridae; Polyomaviridae; or Retroviridae.
23. The method of claim 11, further comprising contacting the cell with one or more of a SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7 agonist.
24. (canceled)
25. The method of claim 1, further comprising contacting the virus with a second agent.
26. The method of claim 25, wherein the second agent is an antiviral agent.
27.-28. (canceled)
29. The method of claim 1, wherein the cell is a tumor cell.
30. The method of claim 29, wherein the tumor cell is infected with HCMV.
31. The method of claim 1, wherein the two or more sirtuins are inhibited by inhibiting gene expression of at least one of the two or more sirtuins.
32.-36. (canceled)
37. The method of claim 1, wherein the contacting is in vitro.
38. The method of claim 1, wherein the contacting is in vivo.
39.-46. (canceled)
47. A method of increasing virus production comprising inhibiting sirtuin gene expression in a virus-infected cell.
48.-54. (canceled)
55. The method of claim 47, wherein the sirtuin gene expression is inhibited by contacting the cell with a dominant negative sirtuin gene, coding sequence or protein.
56. The method of claim 47, wherein the sirtuin gene expression is inhibited in cells from a transgenic animal.
57. The method of claim 47, wherein the sirtuin gene expression is inhibited by mutational inactivation within cultured cells.
US13/982,779 2011-02-02 2012-02-02 Sirtuin modulators as inhibitors of cytomegalovirus Abandoned US20130338178A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/982,779 US20130338178A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as inhibitors of cytomegalovirus

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161438846P 2011-02-02 2011-02-02
US61438846 2011-02-02
US201161527102P 2011-08-24 2011-08-24
US61527102 2011-08-24
US13/982,779 US20130338178A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as inhibitors of cytomegalovirus
PCT/US2012/023621 WO2012106509A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as virus production modulators

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/023621 A-371-Of-International WO2012106509A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as virus production modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/187,269 Continuation US10813934B2 (en) 2011-02-02 2016-06-20 Sirtuin modulators as inhibitors of cytomegalovirus

Publications (1)

Publication Number Publication Date
US20130338178A1 true US20130338178A1 (en) 2013-12-19

Family

ID=45755524

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/982,779 Abandoned US20130338178A1 (en) 2011-02-02 2012-02-02 Sirtuin modulators as inhibitors of cytomegalovirus
US15/187,269 Active US10813934B2 (en) 2011-02-02 2016-06-20 Sirtuin modulators as inhibitors of cytomegalovirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/187,269 Active US10813934B2 (en) 2011-02-02 2016-06-20 Sirtuin modulators as inhibitors of cytomegalovirus

Country Status (6)

Country Link
US (2) US20130338178A1 (en)
EP (1) EP2670404B1 (en)
JP (1) JP2014505705A (en)
CN (1) CN103391777A (en)
DK (1) DK2670404T3 (en)
WO (1) WO2012106509A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147180A1 (en) 2016-02-22 2017-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
WO2018006074A3 (en) * 2016-07-01 2018-02-15 Arrakis Therapeutics, Inc. Compounds and methods for modulating rna function
US10813934B2 (en) 2011-02-02 2020-10-27 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
WO2022026806A1 (en) * 2020-07-30 2022-02-03 University Of Connecticut Methods and compositions for the treatment of viral infections
IT202000023281A1 (en) * 2020-10-02 2022-04-02 Univ Degli Studi Del Piemonte Orientale A Avogadro SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF HPV-INDUCED CANCER
US11807623B2 (en) 2017-11-30 2023-11-07 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6120311B2 (en) * 2013-02-12 2017-04-26 学校法人銀杏学園 Polyphenol compounds
WO2014138562A1 (en) * 2013-03-07 2014-09-12 Glaxosmithkline Llc Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators
EP3073824A4 (en) * 2013-11-25 2017-10-25 Saint Louis University Inhibitors of hsv nucleotidyl transferases and uses therefor
KR101596276B1 (en) 2014-02-27 2016-02-22 한국화학연구원 Pharmaceutical compositions for cancer prevention or treatment comprising the SIRT7 inhibitor
CN104193644B (en) * 2014-09-27 2015-12-02 张远强 The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use
WO2016045115A1 (en) * 2014-09-28 2016-03-31 姜凡 Hiv-1 integrase inhibitor
CN105087811A (en) * 2015-09-18 2015-11-25 重庆医科大学 Application of SIRT3 gene and related drugs of SIRT3 gene
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
KR20180095032A (en) * 2015-12-17 2018-08-24 메르크 파텐트 게엠베하 Cinnamic acid derivative
JP2018024592A (en) * 2016-08-09 2018-02-15 株式会社ブレインヘルス Composition comprising antibiotic
CN110392680A (en) 2016-12-22 2019-10-29 拜耳作物科学股份公司 Substituted oxazolyl pyrrolones and oxazolyl hydantoins and its salt and its purposes as herbicidal active compounds
JP7434154B2 (en) * 2017-11-24 2024-02-20 オタゴ イノベーション リミテッド Pharmaceutical combinations and methods for treating diabetes and related diseases
CN108042524A (en) * 2017-12-21 2018-05-18 南方医科大学 The application of tanshin polyphenolic acid B and its analogue in anti-HPV viruse infection medicine is prepared
CN108619123A (en) * 2018-03-13 2018-10-09 武汉威立得生物医药有限公司 Tenovin-1 is preparing the application in preventing nerpes vinrus hominis's infection medicine
CN109157536A (en) * 2018-07-26 2019-01-08 贵州万里乡村农业开发有限公司 A kind of control method of duck plague disease
CN109394738A (en) * 2018-12-07 2019-03-01 浙江医院 New application of the piceatannol in prevention and treatment human cytomegalovirus infection
CN109876144B (en) * 2019-04-03 2019-11-22 山东大学 Purposes of the EMC8 gene inhibitor in preparation treatment gastric cancer medicament
CN112807294B (en) * 2019-11-18 2023-09-05 武汉大学 Application of acyl thiourea compound in preparation of medicines for treating or preventing herpes simplex virus type I infection
CN113350330B (en) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 Application of myricetin compound in preparation of medicine for preventing and treating new coronary pneumonia
CN112516122A (en) * 2020-04-21 2021-03-19 洪楠方 Application of suramin in preparation of drugs for preventing or treating coronavirus related diseases
WO2022029275A1 (en) * 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
EP3949964A1 (en) * 2020-08-06 2022-02-09 Nuvamid SA Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections
CN114432283A (en) * 2020-10-30 2022-05-06 中国科学院深圳先进技术研究院 Application of SIRTINOL in preparation of medicine for preventing and treating coronavirus
WO2022088037A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of sirtinol in preparation of drug for preventing and treating coronavirus
WO2022192645A1 (en) * 2021-03-12 2022-09-15 The General Hospital Corporation Compounds for brain imaging
WO2023123225A1 (en) * 2021-12-30 2023-07-06 南京紫珑生物科技有限公司 Application of sirt1-7 protein in immunotherapy
WO2023159601A1 (en) * 2022-02-28 2023-08-31 Shenzhen University Use of agent deacetylating klf4 to promote transcriptional activity thereof, method for maintaining functions of pulmonary artery endothelial cells, and method for treating pulmonary arterial hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
US20100113542A1 (en) * 2007-01-18 2010-05-06 Merck Patent Gesellschaft Triazole derivative as an hsp 90 inhibitor

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
AU5012285A (en) * 1984-10-12 1986-05-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en) 1985-01-08 1987-04-03 Pasteur Institut NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
DE3855864T2 (en) 1987-11-30 1997-09-25 Univ Iowa Res Found DNA MOLECULES STABILIZED BY MODIFICATIONS ON THE 3'-TERMINAL PHOSPHODIESTERBINDING, THEIR USE AS NUCLEIC ACID PROBE AND AS A THERAPEUTIC AGENT FOR INHIBITING THE EXPRESSION OF SPECIFIC TARGET GENES
JPH03503894A (en) 1988-03-25 1991-08-29 ユニバーシィティ　オブ　バージニア　アランミ　パテンツ　ファウンデイション Oligonucleotide N-alkylphosphoramidate
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5623065A (en) 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0455905B1 (en) 1990-05-11 1998-06-17 Microprobe Corporation Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
BR9106702A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc ANALOG OF OLIGONUCLEOTIDEOS AND PROCESSES TO MODULATE THE PRODUCTION OF A PROTEIN BY AN ORGANISM AND TO TREAT AN ORGANISM
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
IL99066A (en) 1990-08-03 1996-01-31 Sterling Winthrop Inc Nuclease resistant compounds comprising an oligonucleotide sequence having a diol at either or both termini and compositions containing them
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
JPH06505704A (en) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
DE59208572D1 (en) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
DE637965T1 (en) 1991-11-26 1995-12-14 Gilead Sciences Inc INCREASED FORMATION OF TRIPLE AND DOUBLE HELICOS FROM OLIGOMERS WITH MODIFIED PYRIMIDINES.
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
ATE155467T1 (en) 1993-03-30 1997-08-15 Sanofi Sa ACYCLIC NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE SEQUENCES CONTAINING THEM
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
DE4311944A1 (en) 1993-04-10 1994-10-13 Degussa Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
NZ278490A (en) 1993-12-09 1998-03-25 Univ Jefferson Chimeric polynucleotide with both ribo- and deoxyribonucleotides in one strand and deoxyribonucleotides in a second strand
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5912340A (en) 1995-10-04 1999-06-15 Epoch Pharmaceuticals, Inc. Selective binding complementary oligonucleotides
US6379911B2 (en) 1996-02-23 2002-04-30 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
CN1273476C (en) 1997-09-12 2006-09-06 埃克西康有限公司 Bi-and tri-cyclic nucleoside, nucleotide and oligonucleotide analoguse
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
CA2634299C (en) 1999-04-08 2011-05-31 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
EP1072679A3 (en) 1999-07-20 2002-07-31 Agilent Technologies, Inc. (a Delaware corporation) Method of producing nucleic acid molecules with reduced secondary structure
JP2004507534A (en) 2000-08-29 2004-03-11 インダストリアル　リサーチ　リミテッド Nucleoside metabolism inhibitor
CA2433840C (en) 2001-01-04 2010-05-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof
AU2002356992A1 (en) 2001-11-21 2003-06-10 Albert Einstein College Of Medicine Of Yeshiva University Sir2 products and activities
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US20060014705A1 (en) 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20090137681A1 (en) * 2005-04-08 2009-05-28 David A Sinclair Sirtuin Inhibiting Compounds
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20100137345A1 (en) * 2007-05-14 2010-06-03 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2010077642A1 (en) * 2008-12-08 2010-07-08 Northwestern University Method of modulating hsf-1
JP2014505705A (en) 2011-02-02 2014-03-06 ザ トラスティーズ オブ プリンストン ユニヴァシティ Sirtuin modulators as virus production modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197834B1 (en) * 1998-09-01 2001-03-06 Northeastern Ohio Universities College Of Medicine Method of inhibiting formation of infectious herpes virus particles
US20100113542A1 (en) * 2007-01-18 2010-05-06 Merck Patent Gesellschaft Triazole derivative as an hsp 90 inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pasco et al. "Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrphy protein reveals muscle cell and behavioral protection by specific sirtinol analogues," J. Medicinal Chemistry, 2010, Vol. 53, pp 1407-1411 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813934B2 (en) 2011-02-02 2020-10-27 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
WO2017147180A1 (en) 2016-02-22 2017-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
US11103496B2 (en) 2016-02-22 2021-08-31 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
US11559522B2 (en) 2016-02-22 2023-01-24 The Trustees Of The University Of Pennsylvania Methods for enhancing liver regeneration
WO2018006074A3 (en) * 2016-07-01 2018-02-15 Arrakis Therapeutics, Inc. Compounds and methods for modulating rna function
US11807623B2 (en) 2017-11-30 2023-11-07 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
WO2022026806A1 (en) * 2020-07-30 2022-02-03 University Of Connecticut Methods and compositions for the treatment of viral infections
IT202000023281A1 (en) * 2020-10-02 2022-04-02 Univ Degli Studi Del Piemonte Orientale A Avogadro SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF HPV-INDUCED CANCER

Also Published As

Publication number Publication date
WO2012106509A1 (en) 2012-08-09
CN103391777A (en) 2013-11-13
US10813934B2 (en) 2020-10-27
EP2670404B1 (en) 2018-08-29
JP2014505705A (en) 2014-03-06
EP2670404A1 (en) 2013-12-11
US20160296523A1 (en) 2016-10-13
DK2670404T3 (en) 2018-11-19

Similar Documents

Publication Publication Date Title
US10813934B2 (en) Sirtuin modulators as inhibitors of cytomegalovirus
DK2753316T3 (en) PHARMACEUTICAL COMBINATION INCLUDING A CIP2A SILENCING AGENT TO USE IN THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER, PRIOR TO AN IMPAIRED P53 FUNCTION
JP2015523854A (en) Compositions and methods for modulating SMN gene family expression
US20160201063A1 (en) Epigenetic regulators of frataxin
ES2961686T3 (en) Modulation of apolipoprotein C-III (APOCIII) expression in lipoprotein lipase deficient (LPLD) populations
US11873494B2 (en) Genetic and pharmacological transcriptional upregulation of the repressed FXN gene as a therapeutic strategy for Friedreich ataxia
JP2024023235A (en) Regulators of ENaC expression
JP6001655B2 (en) Combination therapy
US10071098B2 (en) Compositions useful for treating herpes simplex labialis and/or herpes esophagitis, and methods using same
TW202309282A (en) Antiviral nucleic acid
US11045456B2 (en) Compositions and methods for treating COPD and other inflammatory conditions
de León et al. Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals
EP2872631A1 (en) Combination therapy iii
WO2020047229A1 (en) Inhibition of protein kinases to treat friedreich ataxia
JP2023161422A (en) Antiviral nucleic acid with double strand region
Seo et al. Protection against lethal vaccinia virus infection in mice using an siRNA targeting the A5R gene
CN114540384A (en) Oligonucleotides for reducing angiotensin converting enzyme 2(ACE2) expression and their use in treating viral infections

Legal Events

Date Code Title Description
AS Assignment

Owner name: THE TRUSTEES OF PRINCETON UNIVERSITY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOYUNCU, EMRE;SHENK, THOMAS;CRISTEA, ILEANA;SIGNING DATES FROM 20110831 TO 20110902;REEL/FRAME:032013/0057

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:PRINCETON UNIVERSITY;REEL/FRAME:037146/0584

Effective date: 20130808

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:PRINCETON UNIVERSITY;REEL/FRAME:039325/0009

Effective date: 20160713

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:PRINCETON UNIVERSITY;REEL/FRAME:040116/0385

Effective date: 20161025